



City Research Online

City, University of London Institutional Repository

Citation: Sbarra, A.N., Rolfe, S., Nguyen, J. Q., Earl, L., Galles, N. C., Marks, A., Abbas, K. M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., et al (2020). Mapping routine measles vaccination in low- and middle-income countries. *NATURE*, 589(7842), doi: 10.1038/s41586-020-03043-4

This is the published version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/28766/>

Link to published version: <https://doi.org/10.1038/s41586-020-03043-4>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

Mapping routine measles vaccination in low- and middle-income countries

<https://doi.org/10.1038/s41586-020-03043-4>

Local Burden of Disease Vaccine Coverage Collaborators*

Received: 1 May 2020

Accepted: 2 November 2020

Published online: 16 December 2020

Open access

 Check for updates

The safe, highly effective measles vaccine has been recommended globally since 1974, yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in children under 5 years old, and more than 99% of both occurred in low- and middle-income countries (LMICs)^{1–4}. Globally comparable, annual, local estimates of routine first-dose measles-containing vaccine (MCV1) coverage are critical for understanding geographically precise immunity patterns, progress towards the targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions to vaccination programmes caused by coronavirus disease 2019 (COVID-19)^{5–8}. Here we generated annual estimates of routine childhood MCV1 coverage at $5 \times 5\text{-km}^2$ pixel and second administrative levels from 2000 to 2019 in 101 LMICs, quantified geographical inequality and assessed vaccination status by geographical remoteness. After widespread MCV1 gains from 2000 to 2010, coverage regressed in more than half of the districts between 2010 and 2019, leaving many LMICs far from the GVAP goal of 80% coverage in all districts by 2019. MCV1 coverage was lower in rural than in urban locations, although a larger proportion of unvaccinated children overall lived in urban locations; strategies to provide essential vaccination services should address both geographical contexts. These results provide a tool for decision-makers to strengthen routine MCV1 immunization programmes and provide equitable disease protection for all children.

The safe, highly effective vaccine against measles has been recommended since 1974 by the Expanded Programme on Immunization of the WHO (World Health Organization)^{1–3}. A single valid dose of any MCV is approximately 93% effective in providing individuals with lifelong protection from measles¹. Still, in 2017, there were an estimated 17,767,037 new global cases and 83,439 deaths attributable to measles in children under 5 years old⁴. Although high-income regions, such as the USA and Europe, have recently started experiencing extended measles outbreaks due to a lapse in vaccination coverage, more than 99% of cases and deaths still occur in LMICs^{4,9}.

Low vaccination rates and increasing vaccine hesitancy^{10–12} contribute to the persistence of measles as a major cause of childhood morbidity and mortality. National-level MCV1 estimates from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019 identified only 72 out of 204 countries in which routine coverage reached approximate herd immunity targets ($\geq 95\%$) in 2019, and global MCV1 coverage^{4,13} was 84.2%. Even in countries with high national coverage, these estimates mask important subnational heterogeneities that may sustain ongoing disease transmission and increase the risk of outbreaks^{14–17}, especially in light of the current service disruptions associated with the COVID-19 pandemic^{7,8}. Global vaccination initiatives, such as the GVAP and Immunization Agenda 2030, recognize the importance of eliminating subnational coverage disparities, aiming for at least 90% of the target population in every country and 80% in every district to be covered^{5,6}.

Subnational routine MCV1 coverage

Since 2016, the WHO and UNICEF have collected subnational coverage data through their annual Joint Reporting process, although poor data quality and biases currently limit the use of administrative data to track progress towards GVAP targets^{18–20}. For the 101 countries included in this study, 91 reported subnational data in 2018 in a total of 11,311 subnational geographical units. Of these countries, 71 reported MCV1 coverage greater than 100% in at least one unit and 55 reported such coverage in at least a quarter of units. Although researchers have estimated subnational MCV1 coverage in select countries or years for which there have been reliable surveys, to date, no comprehensive analysis of all available vaccine coverage data to produce subnational estimates of MCV1 coverage annually in all LMICs has been undertaken^{21–24}.

Building from our previous work mapping diphtheria–tetanus–pertussis vaccine coverage in Africa¹⁴, here we present mapped high-spatial-resolution estimates of routine MCV1 coverage across 101 LMICs from 2000 to 2019, aggregated to policy-relevant second-level administrative units (hereafter districts). Using geolocated data on MCV1 coverage from 354 household-based surveys representing approximately 1.70 million children and a suite of environmental, sociodemographic and health-related geospatial and national-level covariates, we extended model-based geostatistical methods that have been used to map child mortality and its main components and risk factors^{25–28} to predict MCV1 coverage and uncertainty

*A list of participants and their affiliations appears in the online version of the paper.




Fig. 1 | Estimated MCV1 coverage among districts in 101 LMICs, 2000–2019. a–c, MCV1 coverage among target population in districts in 2000 (a), 2010 (b) and 2019 (c). Countries excluded from the analysis and pixels classified as

‘barren or sparsely vegetated’ based on European Space Agency Climate Change Initiative (ESA-CCI) satellite data or with fewer than 10 people per $1 \times 1\text{-km}^2$ pixel based on WorldPop estimates are masked in grey^{30,50}.

(Extended Data Figs. 1, 2), while calibrating estimates to results from GBD 2019. Using these estimates, we assessed trends in geographical inequality, progress towards global targets and differential vaccination status by geographical remoteness.

Tracking uneven progress

Despite marked global progress between 2000 and 2019, considerable inequalities in routine MCV1 coverage persist, both between and within countries (Fig. 1, Extended Data Figs. 3–7, see also our visualization tool (<https://vizhub.healthdata.org/lbd/mcv>)). MCV1 coverage among children living in the 101 countries included in this study was 65.6% (95% uncertainty interval, 64.2–67.1%) in 2000 and 81.0% (95% uncertainty interval, 79.2–82.7%) in 2019. Coverage increased at the national level in 69.9% (95% uncertainty interval, 64.4–75.2%) of countries between 2000 and 2019 and in 57.4% (95% uncertainty interval, 50.4–64.6%) of districts ($n = 20,795$ districts).

The three districts with the lowest MCV1 coverage in 2000 were located in Hari Rasu, Ethiopia (4.0% (95% uncertainty interval, 1.1–9.7%)), Gabi Rasu, Ethiopia (4.8% (95% uncertainty interval, 1.4–11.4%)), and Isa, Nigeria (4.9% (95% uncertainty interval, 1.5–10.8%)). In 2000, 60 districts had a coverage below 10%; there was one such district in 2019. The three lowest-coverage districts in 2019 were all located in Afghanistan: Poruns (9.2% (95% uncertainty interval, 2.0–25.5%)),

Wama (12.1% (95% uncertainty interval, 2.8–32.6%)) and Waygal (12.7% (95% uncertainty interval, 3.0–34.2%)).

In the period from 2000 to 2010, there were substantial increases in coverage and progress towards reducing subnational heterogeneity. The period from 2010 to 2019, however, showed slowing progress and, in some cases, regression of coverage compared to the 2000–2010 period (Fig. 2). Between 2000 and 2010, 70.5% (95% uncertainty interval, 66.0–75.4%) of districts increased coverage, but between 2010 and 2019, coverage increased in only 40.1% (95% uncertainty interval, 34.2–46.9%) of districts (Extended Data Fig. 8). This finding persists even when accounting for the starting level of coverage (Supplementary Information section 2.3).

Although district-level MCV1 coverage generally increased between 2000 and 2019, further gains are required to reach both 80% and 95% key coverage targets (Extended Data Fig. 9). In 2000, 38.4% of districts had a high probability (>95% posterior probability) of reaching the GVAP target of 80% district-level MCV1 coverage, which remained stagnant at 33.2% of districts in 2019. Only 15 countries had a high probability of reaching the GVAP target of greater than 80% district-level coverage in all districts.

Quantifying geographical inequalities

To further assess the effect of geographical heterogeneity in MCV1 coverage, we computed the absolute geographical inequality,




Fig. 2 | Estimated absolute changes in MCV1 coverage in the early (2000–2010) and late (2010–2019) study periods. a, b, Mean district-level absolute differences in MCV1 coverage from 2000 to 2010 (a) and from 2010 to 2019 (b).

Countries excluded from the analysis and pixels classified as ‘barren or sparsely vegetated’ based on ESA-CCI satellite data or with fewer than 10 people per $1 \times 1\text{-km}^2$ pixel based on WorldPop estimates are masked in grey^{30,50}.

a Gini-coefficient-derived metric that ranges between zero (perfectly homogenous coverage) and one (perfectly heterogeneous coverage), at the $5 \times 5\text{-km}^2$ level. In 2000, nine countries (Cameroon, Democratic Republic of the Congo, Guinea, India, Laos, Madagascar, Mali, Nigeria and Yemen) had high absolute geographical inequality (above 0.15). In 2019, only five countries had high absolute geographical inequality (Angola, Ethiopia, Madagascar, Nigeria and Pakistan). Nigeria had absolute geographical inequality above or equal to 0.2 in both 2000 and 2019, and 25 countries had increased absolute geographical inequality in 2019 compared with 2000. Notably, absolute geographical inequality decreased considerably in India, from 0.23 in 2000 to 0.07 in 2019.

In general, and as expected, improvements in national-level coverage over time were accompanied by reductions in subnational absolute geographical inequality (Fig. 3). Changes in coverage were negatively correlated ($\rho = -0.47$, Pearson’s product moment test statistic = -5.36 , $P < 0.001$) with changes in absolute inequality. India is a true exemplar in this trend, with sizeable reductions in inequality occurring as coverage increased. This improvement was not the only pathway for a country, however; some countries with increasing coverage also experienced increasing inequality, such as Chad and Ethiopia. Other countries experienced decreasing coverage alongside increasing inequality, such as Angola.

Coverage in urban and rural areas

In a post hoc analysis, we compared vaccination status in urban and remote rural settings, using proxies of travel time of ≤ 30 min and ≥ 3 h, respectively, to the nearest major city or settlement²⁹ and the number of children under 5 years old³⁰ from gridded estimates. In 2019, MCV1 coverage was relatively lower in remote rural areas: in remote rural locations, 33.3% of children were MCV-unvaccinated, compared with 15.2% of children living in urban areas. Owing to the concentration of populations in urban centres, however, more unvaccinated children lived in urban locations (47.9% of all unvaccinated children) than remote rural areas (16.0% of all unvaccinated children) in 2019, although this pattern varied across countries and regions (Fig. 4). For example, in

Chad, 19.3% of unvaccinated children lived in urban locations and 44.4% lived in remote rural locations in 2019. In Mexico in 2019, 72.3% of unvaccinated children lived in urban locations and 3.4% lived in remote rural locations (Extended Data Fig. 10).

Our results show the variability of urban and rural contributions to unvaccinated populations in each country and region. In Latin America and the Caribbean, for example, MCV1 coverage is generally similar between urban and rural settings (Fig. 4); the urban–remote rural distribution of unvaccinated children therefore largely reflects the underlying population distribution. In other regions, the interaction between population and coverage is more complex. In South Asia, for example, 21 times more unvaccinated children live in urban locations compared with remote rural locations. Strategies focused solely on reaching the most unvaccinated children possible in that region, therefore, might reasonably prioritize urban areas. Overall, however, MCV1 coverage in urban areas of South Asia averages 90.7%, compared to only 77.4% in remote rural areas. Approaches that focus primarily on reaching urban areas, therefore, would probably exacerbate existing urban–rural coverage inequalities.

Discussion

Our MCV1 coverage estimates show overall progress from 2000 to 2019, corresponding to the creation of benchmark targets from the Measles and Rubella Initiative and GVAP, as well as substantial financial support for comprehensive vaccination programming generated by the introduction of Gavi, the Vaccine Alliance^{5,6,31–34}. Moreover, 62 out of 101 countries increased national-level MCV1 coverage while reducing subnational geographical inequalities over time, a noteworthy achievement.

This remarkable global progress should be celebrated, but this trend was not universal. Our results show a decline and stagnation in routine MCV1 coverage in certain locations, particularly since 2010, that may be related to conflict, vaccine scepticism, available funding support and supply disruptions³⁵. Among countries with stagnant or declining coverage rates, the Central African Republic and Nigeria are experiencing




Fig. 3 | Absolute geographical inequality of MCV1 coverage in 2000 and 2019. We compared the change in geographical absolute inequality to change in national-level coverage from 2000 to 2019. Points are sized by under-5 population size.

ongoing political instability and conflict, which serve as major barriers to the success of vaccination programmes^{36–38}. Supply disruptions also present a major barrier to achieving and sustaining high levels of MCV coverage. For example, in 2018, the Philippines reported a national-level MCV stockout³⁹. The stockout, alongside waning public confidence in vaccination programmes stemming from misinformation related to risks of the Dengvaxia dengue vaccine, contributed to a national-level drop in coverage from 80% to 69% between 2017 and 2018⁴⁰. In Angola, economic turmoil led to a 28% decrease in governmental health spending per capita between 2010 and 2018, which may have also contributed to declines in vaccination coverage⁴¹. While global immunization initiatives have often focused on low-income countries, districts in middle-income countries also experienced recent declines, emphasizing the need for reliable immunization programmes and monitoring in these nations⁴². In Indonesia, for instance, 3 districts had coverage that reached 95% in 2000, increasing to 13 in 2010, but decreasing back to zero in 2019. In addition, countries with higher than average vaccine scepticism, such as Peru and Moldova, also experienced decreasing coverage rates and increasing within-country inequality⁴³.

Overlaid on these persistent challenges, the ongoing COVID-19 pandemic has caused the cancellation of supplementary measles immunization campaigns and puts the delivery of critical routine immunization services at risk⁷⁸. Baseline subnational estimates of routine MCV1 immunization in LMICs can help to define the geographical areas of highest vulnerability to pandemic-associated disruptions. To mitigate the risk of measles outbreaks in the setting of the COVID-19 pandemic, the maintenance of routine immunization services is crucial⁴⁴—particularly in areas with pre-existing routine immunization weaknesses.

Even before the current pandemic, few countries reached the GVAP target of 80% coverage in all districts by 2019. Stagnant progress




Fig. 4 | Vaccination status in 2019 and geographical remoteness. Cumulative proportion of unvaccinated children living within the spectrum of the travel time (in hours) to a major city or settlement per region (left) and coverage among children living within the spectrum of travel time to a major city or settlement per region (right). Vertical dashed grey line shows thresholds for ‘urban’ and ‘remote rural’, living within 30 min and at least 3 h from a major city or settlement, respectively.

between 2010 and 2019 further suggests that new approaches are needed to reach unvaccinated children and resolve geographical inequalities. As the era of GVAP draws to a close and the Immunization Agenda 2030 begins, these results provide a platform to identify successes and inform strategies for the next decade. India, for instance, saw exemplary improvement in both national-level coverage and geographical equality over time. This may be attributable to specific interventions such as Mission Indradhanush, launched in 2014 with the goal of targeting underserved unvaccinated populations⁴⁵. In addition, India introduced a second dose of MCV (MCV2) in select subnational geographies with MCV1 coverage below 80% starting in 2008, and expanded MCV2 to cover all districts in 2010 through the strengthening of both routine and supplementary immunization programmes^{46,47}. The introduction of MCV2 into the national schedule may provide a second opportunity for first-dose vaccination among children who missed the scheduled MCV1 dose. Understanding the specific drivers of simultaneous coverage and equality gains may provide critical insights for the immunization agenda in countries and regions that have fallen behind.

The Equity Reference Group for Immunization highlights the need for increased attention on vaccinating vulnerable children who live in remote rural, urban poor and conflict settings, as well as for equality in coverage by gender⁴⁸. These recommendations suggest that the agenda to leave no child unvaccinated, set by global partners and the Sustainable Development Goals, should transcend geography types and aim to eliminate coverage gaps among children who live in both urban and remote rural areas⁴⁹. These geographically resolved MCV1 estimates provide a tool for decision-makers to plan supplementary immunization activities and routine immunization strengthening programmes, to reach both the urban and remote rural communities where unvaccinated children live.

Despite large improvements made in MCV1 coverage from routine immunization programmes between 2000 and 2019, stalling progress and substantial subnational variation remain in many LMICs, leaving children at risk of preventable death. Policymakers should note where progress is most critically needed to successfully meet global immunization targets and protect the most-vulnerable children against measles. Our subnational estimates of routine MCV1 coverage at policy-relevant scales provide a tool for decision-makers to use in advocating for strong, sustainable immunization programmes that provide equitable protection for all children.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-020-03043-4>.

- McLean, H. Q., Fiebelkorn, A. P., Temte, J. L. & Wallace, G. S. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of Advisory Committee on Immunization Practices (ACIP). *MMWR Morb. Mortal. Wkly Rep.* **62**, 1–34 (2013).
- Keja, K., Chan, C., Hayden, G. & Henderson, R. H. Expanded programme on immunization. *World Health Stat. Q.* **41**, 59–63 (1988).
- World Health Assembly. *WHO Expanded Programme on Immunization* (World Health Organization, 1974).
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1204–1222 (2020).
- WHO. *Global Vaccine Action Plan 2011–2020*. http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/ (2012).
- WHO. *Immunization Agenda 2030: A Global Strategy to Leave No One Behind*. http://www.who.int/immunization/immunization_agenda_2030/en/ (2020).
- Roberts, L. Polio, measles, other diseases set to surge as COVID-19 forces suspension of vaccination campaigns. *Science* <https://www.sciencemag.org/news/2020/04/polio-measles-other-diseases-set-surge-covid-19-forces-suspension-vaccination-campaigns> (9 April 2020).
- Nelson, R. COVID-19 disrupts vaccine delivery. *Lancet Infect. Dis.* **20**, 546 (2020).
- WHO. *New Measles Surveillance Data from WHO*. <http://www.who.int/immunization/newsroom/new-measles-data-august-2019/en/> (2019).
- Center for Disease Control and Prevention. *Global Measles Outbreaks*. <https://www.cdc.gov/globalhealth/measles/globalmeaslesoutbreaks.htm> (2019).
- Glass, K., Kappey, K. & Grenfell, B. T. The effect of heterogeneity in measles vaccination on population immunity. *Epidemiol. Infect.* **132**, 675–683 (2004).
- Larson, H. J. et al. The state of vaccine confidence 2016: global insights through a 67-country survey. *EBioMedicine* **12**, 295–301 (2016).
- Plotkin, S., Orenstein, W., Offit, P. & Edwards, K. M. *Plotkin's Vaccines* (Elsevier, 2017).
- Mosser, J. F. et al. Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000–2016: a spatial and temporal modelling study. *Lancet* **393**, 1843–1855 (2019).
- Truelove, S. A. et al. Characterizing the impact of spatial clustering of susceptibility for measles elimination. *Vaccine* **37**, 732–741 (2019).
- Verguet, S. et al. Measles control in sub-Saharan Africa: South Africa as a case study. *Vaccine* **30**, 1594–1600 (2012).
- Ferrari, M. J., Grenfell, B. T. & Strebel, P. M. Think globally, act locally: the role of local demographics and vaccination coverage in the dynamic response of measles infection to control. *Phil. Trans. R. Soc. B* **368**, 20120141 (2013).
- WHO. *WHO/UNICEF Joint Reporting Process*. http://www.who.int/immunization/monitoring_surveillance/routine/reporting/en/ (2019).
- Brown, D. W. Definition and use of “valid” district level vaccination coverage to monitor Global Vaccine Action Plan (GVAP) achievement: evidence for revisiting the district indicator. *J. Glob. Health* **8**, 020404 (2018).
- Lim, S. S., Stein, D. B., Charrow, A. & Murray, C. J. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. *Lancet* **372**, 2031–2046 (2008).
- Utazi, C. E. et al. High resolution age-structured mapping of childhood vaccination coverage in low and middle income countries. *Vaccine* **36**, 1583–1591 (2018).
- Takahashi, S., Metcalf, C. J. E., Ferrari, M. J., Tatem, A. J. & Lessler, J. The geography of measles vaccination in the African Great Lakes region. *Nat. Commun.* **8**, 15585 (2017).
- Kundrick, A. et al. Sub-national variation in measles vaccine coverage and outbreak risk: a case study from a 2010 outbreak in Malawi. *BMC Public Health* **18**, 741 (2018).
- Utazi, C. E. et al. Mapping vaccination coverage to explore the effects of delivery mechanisms and inform vaccination strategies. *Nat. Commun.* **10**, 1633 (2019).
- Dwyer-Lindgren, L. et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. *Nature* **570**, 189–193 (2019).
- Burstein, R. et al. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. *Nature* **574**, 353–358 (2019).
- Local Burden of Disease Educational Attainment Collaborators. Mapping disparities in education across low- and middle-income countries. *Nature* **577**, 235–238 (2020).
- Local Burden of Disease Child Growth Failure Collaborators. Mapping child growth failure across low- and middle-income countries. *Nature* **577**, 231–234 (2020).
- Weiss, D. J. et al. A global map of travel time to cities to assess inequalities in accessibility in 2015. *Nature* **553**, 333–336 (2018).
- Tatem, A. J. WorldPop, open data for spatial demography. *Sci. Data* **4**, 170004 (2017).
- WHO. *Global Measles and Rubella Strategic Plan: 2012–2020*. <http://apps.who.int/iris/bitsstream/10665/44855/1/9789241503396%5Feng.pdf> (2012).
- Global Burden of Disease Health Financing Collaborator Network. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. *Lancet* **393**, 2233–2260 (2019).
- Muraskin, W. et al. in *Public–Private Partnerships for Public Health* Ch. 6 (ed. Reich, M. R.) 115–168 (Harvard Center for Population and Development Studies, 2002).
- Ikilezi, G., Augusto, O. J., Dieleman, J. L., Sherr, K. & Lim, S. S. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: evidence from 120 low and middle income recipient countries. *Vaccine* **38**, 588–596 (2020).
- Piot, P. et al. Immunization: vital progress, unfinished agenda. *Nature* **575**, 119–129 (2019).
- Council on Foreign Relations. Violence in the Central African Republic. *Global Conflict Tracker* <https://cfr.org/interactive/global-conflict-tracker/conflict/violence-central-african-republic> (2019).
- Mashal, T., Nakamura, K., Kizuki, M., Seino, K. & Takano, T. Impact of conflict on infant immunisation coverage in Afghanistan: a countrywide study 2000–2003. *Int. J. Health Geogr.* **6**, 23 (2007).
- Council on Foreign Relations. Boko Haram in Nigeria. *Global Conflict Tracker* <https://cfr.org/interactive/global-conflict-tracker/conflict/boko-haram-nigeria> (2019).
- WHO. *Data, Statistics and Graphics*. http://www.who.int/immunization/monitoring_surveillance/data/en/ (accessed 30 April 2020).
- Larson, H. J., Hartigan-Go, K. & de Figueiredo, A. Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness. *Hum. Vaccin. Immunother.* **15**, 625–627 (2019).
- Institute for Health Metrics and Evaluation (IHME). *Financing Global Health 2018: Countries and Programs in Transition*. http://www.healthdata.org/sites/default/files/files/policy_report/FGH/2019/FGH_2018_full-report.pdf (University of Washington, 2019).
- Berkley, S. Vaccination lags behind in middle-income countries. *Nature* **569**, 309 (2019).
- Wellcome Trust. *Wellcome Global Monitor 2018: How does the World feel about Science and Health?* <https://wellcome.ac.uk/sites/default/files/wellcome-global-monitor-2018.pdf> (2019).
- WHO. *Maintaining Essential Health Services: Operational Guidance for the COVID-19 Context Interim Guidance*. <https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak> (2020).
- Gurnani, V. et al. Improving vaccination coverage in India: lessons from Intensified Mission Indradhanush, a cross-sectoral systems strengthening strategy. *Br. Med. J.* **363**, k4782 (2018).
- Centers for Disease Control and Prevention. Progress in implementing measles mortality reduction strategies—India, 2010–2011. *MMWR Morb. Mortal. Wkly Rep.* **60**, 1315–1319 (2011).
- Masresha, B. G. et al. Introduction of the second dose of measles containing vaccine in the childhood vaccination programs within the WHO Africa Region – lessons learnt. *J. Immunol. Sci.* **S017**, 113–121 (2018).
- ERG. *Equality Reference Group for Immunization: Advocacy Brief*. <https://sites.google.com/view/erg4immunisation> (accessed 30 April 2020).
- United Nations Department of Economic and Social Affairs (UNDESA). *Sustainable Development Goals: The 17 Goals*. <https://sustainabledevelopment.un.org/?menu=1300> (2019).
- ESA-CCI Project. *Land Cover Classification Gridded Maps from 1992 to Present Derived from Satellite Observations*. <https://cds.climate.copernicus.eu/cdsapp#!dataset/satellite-land-cover?tab=overview> (accessed 30 April 2020).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

**Fatemeh Zarej⁶⁷³, Taddese Alemu Zerfu^{674,675}, Yunqian Zhang^{676,677}, Zhi-Jiang Zhang⁶⁷⁸,
Xiu-Ju George Zhao^{679,680}, Maigeng Zhou⁶⁸¹, Arash Ziapour⁶⁸², Simon I. Hay^{151,682},
Stephen S. Lim^{151,682} & Jonathan F. Mosser^{1,151,682}**

¹Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ²Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. ³Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴Advanced Diagnostic and Interventional Radiology Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁵Department of Neurology, Cairo University, Cairo, Egypt. ⁶The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. ⁷School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ⁸Department of Biostatistics, Near East University, Nicosia, Cyprus. ⁹Department of Biostatistics and Health Informatics, Madda Walabu University, Bale Robe, Ethiopia. ¹⁰Department of Public Health, Debre Markos University, Debre Markos, Ethiopia. ¹¹School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia. ¹²Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Sweden. ¹³Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran. ¹⁴Department of Pediatric Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil. ¹⁵Department of Research, Philippine Institute for Development Studies, Quezon City, The Philippines. ¹⁶Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. ¹⁷Department of Medicine, Ain Shams University, Cairo, Egypt. ¹⁸Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK. ¹⁹Clinical Research and Operations, Foundation for Scientific Research (FORS), Cotonou, Benin. ²⁰Hamadan University of Medical Sciences, Hamadan, Iran. ²¹College of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ²²Population Health Sciences, King's College London, London, UK. ²³Centre of Excellence for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa. ²⁴Department of Global Health, Stellenbosch University, Cape Town, South Africa. ²⁵School of Health, Ardebil University of Medical Science, Ardebil, Iran. ²⁶Department of Dermatology, Mayo Clinic, Rochester, MN, USA. ²⁷Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²⁸Department of Epidemiology and Biostatistics, Qom University of Medical Sciences, Qom, Iran. ²⁹Department of Epidemiology and Health Statistics, Southeast University, Nanjing, China. ³⁰Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ³¹Department of Food Science and Technology, University of Tabriz, Tabriz, Iran. ³²Lincoln Medical School, Universities of Nottingham & Lincoln, Lincoln, UK. ³³Department of Epidemiology, Jimma University, Jimma, Ethiopia. ³⁴Australian Center for Precision Health, University of South Australia, Adelaide, South Australia, Australia. ³⁵Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ³⁶Health Information Management and Technology Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ³⁷Center for Health System Research, National Institute of Public Health, Cuernavaca, Mexico. ³⁸Department of Medical Laboratory Science, Woldia University, Woldia, Ethiopia. ³⁹Erbil Technical Health College, Erbil Polytechnic University, Erbil, Iraq. ⁴⁰School of Pharmacy, Tishk International University, Erbil, Iraq. ⁴¹Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan. ⁴²Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. ⁴³Department of Health Care Management and Economics, Urmia University of Medical Science, Urmia, Iran. ⁴⁴Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. ⁴⁵Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁴⁶Health Economics Department, Iran University of Medical Sciences, Tehran, Iran. ⁴⁷Infectious and Tropical Disease Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. ⁴⁸Department of Health Policy and Management, Kuwait University, Safat, Kuwait. ⁴⁹International Centre for Casemix and Clinical Coding, National University of Malaysia, Bandar Tun, Razak, Malaysia. ⁵⁰Department of Environmental Health Engineering, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵¹Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran. ⁵²Medical Research Center, Jazan University, Jazan, Saudi Arabia. ⁵³Department of Parasitology, Sana'a University, Sana'a, Yemen. ⁵⁴Pediatric Intensive Care Unit, King Saud University, Riyadh, Saudi Arabia. ⁵⁵Department of Pharmacology, Mekelle University, Mekelle, Ethiopia. ⁵⁶Health Services Management Department, Arak University of Medical Sciences, Arak, Iran. ⁵⁷Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ⁵⁸Department of Radiology and Nuclear Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵⁹Department of Epidemiology and Biostatistics, University of the Philippines Manila, Manila, The Philippines. ⁶⁰School of Public Health, Johns Hopkins University, Baltimore, MD, USA. ⁶¹Maternal and Child Wellbeing, African Population and Health Research Center, Nairobi, Kenya. ⁶²Pharmacy Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁶³Cardiology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁶⁴Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. ⁶⁵Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ⁶⁶Razi Vaccine and Serum Research Institute, Agricultural Research, Education, and Extension Organization (AREEO), Tehran, Iran. ⁶⁷Department of Epidemiology and Biostatistics, Zahedan University of Medical Sciences, Zahedan, Iran. ⁶⁸Department of Public Health, Debre Berhan University, Debre Berhan, Ethiopia. ⁶⁹Department of Health Policy and Administration, University of the Philippines Manila, Manila, The Philippines. ⁷⁰Department of Applied Social Sciences, Hong Kong Polytechnic University, Hong Kong, China. ⁷¹Agribusiness Study Program, Sebelas Maret University, Surakarta, Indonesia. ⁷²Department of Parasitology, Mazandaran University of Medical Sciences, Sari, Iran. ⁷³Department of Parasitology, Iranshahr University of Medical Sciences, Iranshahr, Iran. ⁷⁴Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran. ⁷⁵Department of Public Health, Birmingham City University, Birmingham, UK. ⁷⁶Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran. ⁷⁷Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran. ⁷⁸Monitoring Evaluation and Operational Research Project, Abt Associates Nepal, Lalitpur, Nepal. ⁷⁹School of Nursing and Midwifery, Babol University of Medical Sciences, Babol, Iran. ⁸⁰Babol University of Medical Sciences, Babol, Iran. ⁸¹Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁸²Prevention of Metabolic Disorders Research

Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁸³Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁸⁴School of Business, University of Leicester, Leicester, UK. ⁸⁵Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania. ⁸⁶Department of Nursing, Wolaita Sodo University, Wolaita Sodo, Ethiopia. ⁸⁷The Judith Lumley Centre, La Trobe University, Melbourne, Victoria, Australia. ⁸⁸Department of Health Policy Planning and Management, University of Health and Allied Sciences, Ho, Ghana. ⁸⁹Department of Nursing, Debre Berhan University, Debre Berhan, Ethiopia. ⁹⁰Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran. ⁹¹Public Health Risk Sciences Division, Public Health Agency of Canada, Toronto, Ontario, Canada. ⁹²Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. ⁹³Department of Forensic Science, Government Institute of Forensic Science, Nagpur, India. ⁹⁴Department of Healthcare Management and Education, Shiraz University of Medical Sciences, Shiraz, Iran. ⁹⁵Unit of Biochemistry, Sultan Zainal Abidin University (Universiti Sultan Zainal Abidin), Kuala Terengganu, Malaysia. ⁹⁶Department of Health Policy, Management, and Economics, Tehran University of Medical Sciences, Tehran, Iran. ⁹⁷Department of Medical Microbiology, Haramaya University, Harar, Ethiopia. ⁹⁸Department of Hypertension, Medical University of Lodz, Lodz, Poland. ⁹⁹Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland. ¹⁰⁰Department of Non-communicable Diseases, Bangladesh University of Health Sciences, Dhaka, Bangladesh. ¹⁰¹Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Belgrade, Serbia. ¹⁰²Faculty of Medicine, University of Belgrade, Belgrade, Serbia. ¹⁰³Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. ¹⁰⁴Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia. ¹⁰⁵Center for Primary Care, Harvard University, Boston, MA, USA. ¹⁰⁶School of Public Health, Imperial College London, London, UK. ¹⁰⁷Health Human Resources Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ¹⁰⁸Monitoring, Evaluation and Research Department, JSI Research & Training Institute, Addis Ababa, Ethiopia. ¹⁰⁹Department of Community Medicine, Gandhi Medical College Bhopal, Bhopal, India. ¹¹⁰Jazan University, Jazan, Saudi Arabia. ¹¹¹Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. ¹¹²School of the Environment, Yale University, New Haven, CT, USA. ¹¹³Department of Public Health, Arba Minch University, Arba Minch, Ethiopia. ¹¹⁴Department of Nutrition and Dietetics, Mekelle University, Mekelle, Ethiopia. ¹¹⁵Department of Global Health, Global Institute for Interdisciplinary Studies, Kathmandu, Nepal. ¹¹⁶Centre for Global Child Health, University of Toronto, Toronto, Ontario, Canada. ¹¹⁷Centre of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan. ¹¹⁸Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran. ¹¹⁹Department of Pediatrics and Child Health Nursing, Bahir Dar University, Bahir Dar, Ethiopia. ¹²⁰Global Health Division, Research Triangle Institute International, Research Triangle Park, NC, USA. ¹²¹School of Medicine, University of Nottingham, Nottingham, UK. ¹²²Department of Neurology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India. ¹²³Department of Veterinary Medicine, Islamic Azad University, Kermanshah, Iran. ¹²⁴Department of Biomedical Sciences, Nazarbayer University, Nur-Sultan City, Kazakhstan. ¹²⁵Department of Endocrinology, Hamadan University of Medical Sciences, Hamadan, Iran. ¹²⁶University of Genoa, Genoa, Italy. ¹²⁷Department of Biomedical Technologies, Bauman Moscow State Technical University, Moscow, Russia. ¹²⁸Department of Epidemiology and Evidence Based Medicine, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. ¹²⁹Department of Community Medicine, Employee State Insurance Post Graduate Institute of Medical Sciences and Research, Bangalore, India. ¹³⁰School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada. ¹³¹Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan. ¹³²Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. ¹³³Board of Directors, Argentine Society of Medicine, Buenos Aires, Argentina. ¹³⁴Health and Nutrition Research Center, National Institute of Public Health, Cuernavaca, Mexico. ¹³⁵Centre for Population Health Sciences, Nanyang Technological University, Singapore, Singapore. ¹³⁶Department of Primary Care and Public Health, Imperial College London, London, UK. ¹³⁷Department of Health Care, Metropolitan Autonomous University, Mexico City, Mexico. ¹³⁸Research Unit on Applied Molecular Biosciences (UCIBIO), University of Porto, Porto, Portugal. ¹³⁹Department of Psychiatry, University of São Paulo, São Paulo, Brazil. ¹⁴⁰Gorgas Memorial Institute for Health Studies, Panama City, Panama. ¹⁴¹Department of Medicine, University of Toronto, Toronto, Ontario, Canada. ¹⁴²Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran. ¹⁴³Epidemiology Research Center, Royan Institute, Tehran, Iran. ¹⁴⁴Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. ¹⁴⁵Melbourne Medical School, University of Melbourne, Parkville, Victoria, Australia. ¹⁴⁶Faculty of Biology, Hanoi National University of Education, Hanoi, Vietnam. ¹⁴⁷Environmental Health Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ¹⁴⁸Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy. ¹⁴⁹Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA. ¹⁵⁰Public Health Foundation of India, Gurugram, India. ¹⁵¹Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. ¹⁵²Indian Council of Medical Research, New Delhi, India. ¹⁵³Immunization, Vaccines and Biologicals (IVB), World Health Organization (WHO), Geneva, Switzerland. ¹⁵⁴Global Delivery Programs, Bill & Melinda Gates Foundation, Seattle, WA, USA. ¹⁵⁵Department of Information Technology, University of Human Development, Sulaymaniyah, Iraq. ¹⁵⁶Department of Pediatrics, Tanta University, Tanta, Egypt. ¹⁵⁷Division of Women and Child Health, Aga Khan University, Karachi, Pakistan. ¹⁵⁸Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany. ¹⁵⁹Department of Medical Laboratory Sciences, Bahir Dar University, Bahir Dar, Ethiopia. ¹⁶⁰Department of Nursing, Woldia University, Woldia, Ethiopia. ¹⁶¹School of Nursing, Jimma University, Jimma, Ethiopia. ¹⁶²Center for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Mexico. ¹⁶³School of Nursing and Midwifery, Haramaya University, Harar, Ethiopia. ¹⁶⁴School of Pharmacy, Mekelle University, Mekelle, Ethiopia. ¹⁶⁵Department of Community Medicine, University of Peradeniya, Peradeniya, Sri Lanka. ¹⁶⁶Department of Microbiology, Far Western University, Mahendranagar, Nepal. ¹⁶⁷Department of Epidemiology and Biostatistics, Shahroud University of Medical Sciences, Shahroud, Iran. ¹⁶⁸Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran. ¹⁶⁹Center of Complexity Sciences, National Autonomous University of Mexico, Mexico City, Mexico. ¹⁷⁰Faculty of Veterinary Medicine and

Article

- Zootechnics, Autonomous University of Sinaloa, Culiacán Rosales, Mexico. ¹⁷¹Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria. ¹⁷²Institute of Health Economics and Technology, Hanoi, Vietnam. ¹⁷³Department of Medical Laboratory Sciences, Iran University of Medical Sciences, Tehran, Iran. ¹⁷⁴Department of Health Policy and Management, Tabriz University of Medical Sciences, Tabriz, Iran. ¹⁷⁵School of Medicine, Western Sydney University, Sydney, New South Wales, Australia. ¹⁷⁶Health Sciences, Royal Melbourne Institute of Technology University, Melbourne, Victoria, Australia. ¹⁷⁷Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. ¹⁷⁸Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand. ¹⁷⁹School of Medicine, Federal University of Bahia, Salvador, Brazil. ¹⁸⁰Department of Internal Medicine, Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil. ¹⁸¹Department of Epidemiology, Florida International University, Miami, FL, USA. ¹⁸²Department of Bacteriology and Virology, Tabriz University of Medical Sciences, Tabriz, Iran. ¹⁸³School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia. ¹⁸⁴Centre Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, New South Wales, Australia. ¹⁸⁵Department of Pharmacology and Toxicology, Maragheh University of Medical Sciences, Maragheh, Iran. ¹⁸⁶Department of Pharmacology and Toxicology, The John Paul II Catholic University of Lublin, Lublin, Poland. ¹⁸⁷Biomedical Informatics and Medical Statistics Department, Alexandria University, Alexandria, Egypt. ¹⁸⁸Reference Laboratory of Egyptian Universities Hospitals, Ministry of Higher Education and Research, Cairo, Egypt. ¹⁸⁹Department of Food Science and Nutrition, Arsi University, Asella, Ethiopia. ¹⁹⁰Neurophysiology Department, Cairo University, Cairo, Egypt. ¹⁹¹Endemic Medicine and Hepatogastroenterology Department, Cairo University, Cairo, Egypt. ¹⁹²Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran. ¹⁹³Department of Microbiology and Immunology, Suez Canal University, Ismailia, Egypt. ¹⁹⁴Department of Medicinal Chemistry, Kerman University of Medical Sciences, Kerman, Iran. ¹⁹⁵Pharmaceutics Research Center, Kerman University of Medical Sciences, Kerman, Iran. ¹⁹⁶Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran. ¹⁹⁷Department of Physiology, Tarbiat Modares University, Tehran, Iran. ¹⁹⁸Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran. ¹⁹⁹Department of Public Health, Maragheh University of Medical Sciences, Maragheh, Iran. ²⁰⁰Unit of Medical Physiology, Hawassa University, Hawassa, Ethiopia. ²⁰¹School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. ²⁰²College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. ²⁰³Department of Medical Parasitology, Mazandaran University of Medical Sciences, Sari, Iran. ²⁰⁴Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. ²⁰⁵Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²⁰⁶Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²⁰⁷Department of Environmental Health Engineering, Ardabil University of Medical Science, Ardabil, Iran. ²⁰⁸Department of Environmental Health Engineering, Tehran University of Medical Sciences, Tehran, Iran. ²⁰⁹Department of Neurobiology, Karolinska Institute, Stockholm, Sweden. ²¹⁰Division of Neurology, University of Ottawa, Ottawa, Ontario, Canada. ²¹¹Associated Laboratory for Green Chemistry (LAQV), University of Porto, Porto, Portugal. ²¹²Psychiatry Department, Kaiser Permanente, Fontana, CA, USA. ²¹³School of Health Sciences, A. T. Still University, Mesa, AZ, USA. ²¹⁴Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany. ²¹⁵Institute of Gerontology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine. ²¹⁶Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria. ²¹⁷Department of Medical Parasitology, Abadan Faculty of Medical Sciences, Abadan, Iran. ²¹⁸Department of Dermatology, Kobe University, Kobe, Japan. ²¹⁹Gillings School of Global Public Health, University of North Carolina Chapel Hill, Chapel Hill, NC, USA. ²²⁰Department of Public Health, Madda Walabu University, Bale Robe, Ethiopia. ²²¹Menelik-II College of Medical and Health Sciences, Kotebe Metropolitan University, Addis Ababa, Ethiopia. ²²²School of Public Health, Mekelle University, Mekelle, Ethiopia. ²²³Department of Nursing and Midwifery, Addis Ababa University, Addis Ababa, Ethiopia. ²²⁴Department of Nursing, Aksum University, Aksum, Ethiopia. ²²⁵Department of Nursing, Mekelle University, Mekelle, Ethiopia. ²²⁶Department of Reproductive Health, Mekelle University, Mekelle, Ethiopia. ²²⁷Department of Midwifery, Woldia University, Woldia, Ethiopia. ²²⁸Department of Biostatistics, Mekelle University, Mekelle, Ethiopia. ²²⁹Infectious Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²³⁰Pediatric Department, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²³¹Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ²³²Department of Parasitology and Entomology, Tarbiat Modares University, Tehran, Iran. ²³³Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran. ²³⁴Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran. ²³⁵Student Research Committee, Iran University of Medical Sciences, Tehran, Iran. ²³⁶Institute of Health Research, University of Exeter, Exeter, UK. ²³⁷Young Researchers and Elite Club, Islamic Azad University, Rasht, Iran. ²³⁸Department of Biology, Islamic Azad University, Tehran, Iran. ²³⁹Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan. ²⁴⁰Afro-Asian Institute, Lahore, Pakistan. ²⁴¹Medical School, University of Warwick, Coventry, UK. ²⁴²Department of Chemistry, University of Porto, Porto, Portugal. ²⁴³Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ²⁴⁴Department of Health and Social Affairs, Government of the Federated States of Micronesia, Palikir, Federated States of Micronesia. ²⁴⁵Postgraduate Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. ²⁴⁶Department of Dermatology, Boston University, Boston, MA, USA. ²⁴⁷Institute of Tropical Pathology and Public Health (IPTSP), Federal University of Goiás, Goiânia, Brazil. ²⁴⁸Department of Epidemiology, Binzhou Medical University, Yantai City, China. ²⁴⁹Medical Resources, March of Dimes, Arlington, VA, USA. ²⁵⁰Health Policy, Management and Leadership, West Virginia University School of Public Health, Morgantown, WV, USA. ²⁵¹Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA. ²⁵²School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ²⁵³Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran. ²⁵⁴Obesity Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²⁵⁵Department of Public Health, Wachemo University, Hossana, Ethiopia. ²⁵⁶University Institute of Public Health, The University of Lahore, Lahore, Pakistan. ²⁵⁷Tabriz University of Medical Sciences, Tabriz, Iran. ²⁵⁸Department of Zoology and Entomology, Al Azhar University, Cairo, Egypt. ²⁵⁹Institute for Social Science Research, The University of Queensland, Indooroopilly, Queensland, Australia. ²⁶⁰ARC Centre of Excellence for Children and Families over the Life Course, The University of Queensland, Indooroopilly, Queensland, Australia. ²⁶¹Department of Healthcare Management, Maragheh University of Medical Sciences, Maragheh, Iran. ²⁶²Department of Microbiology, Maragheh University of Medical Sciences, Maragheh, Iran. ²⁶³Department of Microbiology, Tehran University of Medical Sciences, Tehran, Iran. ²⁶⁴Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. ²⁶⁵Caspian Digestive Disease Research Center, Guilan University of Medical Sciences, Rasht, Iran. ²⁶⁶School of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran. ²⁶⁷Independent Consultant, Tabriz, Iran. ²⁶⁸School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. ²⁶⁹Big Data Institute, University of Oxford, Oxford, UK. ²⁷⁰School of Business, London South Bank University, London, UK. ²⁷¹Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²⁷²Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Iran. ²⁷³Centre for Bio Cultural Studies (CBiCS), Manipal Academy of Higher Education, Manipal, India. ²⁷⁴Department of Pharmacology, Bangladesh Industrial Gases Limited, Tangail, Bangladesh. ²⁷⁵Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran. ²⁷⁶Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²⁷⁷Institute of Research and Development, Duy Tan University, Da Nang, Vietnam. ²⁷⁸Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq. ²⁷⁹College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar. ²⁸⁰Department of Epidemiology and Health Statistics, Central South University, Changsha, China. ²⁸¹School of Public Health, University of Sydney, Sydney, New South Wales, Australia. ²⁸²Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh. ²⁸³Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan. ²⁸⁴Department of Community Medicine, University of Ibadan, Ibadan, Nigeria. ²⁸⁵Department of Community Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ²⁸⁶Department of Epidemiology, University of Kragujevac, Kragujevac, Serbia. ²⁸⁷Department of Public Health, Lorestan University of Medical Sciences, Khorramabad, Iran. ²⁸⁸Division of Community Health and Family Medicine, Bangalore Baptist Hospital, Bangalore, India. ²⁸⁹College of Public Health, Taipei Medical University, Taipei, Taiwan. ²⁹⁰Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²⁹¹Institute for Physical Activity and Nutrition, Deakin University, Burwood, Victoria, Australia. ²⁹²Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia. ²⁹³School of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia. ²⁹⁴South African Medical Research Council, Cape Town, South Africa. ²⁹⁵School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. ²⁹⁶Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran. ²⁹⁷Department of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran. ²⁹⁸School of Management and Medical Education, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²⁹⁹Safety Promotion and Injury Prevention Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁰⁰N. A. Semashko Department of Public Health and Healthcare, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. ³⁰¹Department of Global Health, Economics and Policy, University of Kragujevac, Kragujevac, Serbia. ³⁰²Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. ³⁰³Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ³⁰⁴Department of Medical Mycology, Mazandaran University of Medical Sciences, Sari, Iran. ³⁰⁵Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. ³⁰⁶The George Institute for Global Health, New Delhi, India. ³⁰⁷Manipal Academy of Higher Education, Manipal, India. ³⁰⁸Environmental Research Center, Duke Kunshan University, Kunshan, China. ³⁰⁹Nicholas School of the Environment, Duke University, Durham, NC, USA. ³¹⁰Renal and Cardiovascular Division, The George Institute for Global Health, New Delhi, India. ³¹¹Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia. ³¹²Department of Family Medicine and Public Health, University of Opole, Opole, Poland. ³¹³School of Public Health, University College Cork, Cork, Ireland. ³¹⁴Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran. ³¹⁵Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran. ³¹⁶School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran. ³¹⁷Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. ³¹⁸Health Services Management Department, Qazvin University of Medical Sciences, Qazvin, Iran. ³¹⁹Department of Pharmacy, Shaheed Benazir Bhutto University, Upper Dir, Pakistan. ³²⁰School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China. ³²¹Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Jodhpur, India. ³²²Department of Epidemiology, Hamadan University of Medical Sciences, Hamadan, Iran. ³²³Institute for Epidemiology and Social Medicine, University of Münster, Münster, Germany. ³²⁴Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ³²⁵International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria. ³²⁶Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, The Netherlands. ³²⁷Open, Distance and eLearning Campus, University of Nairobi, Nairobi, Kenya. ³²⁸Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan. ³²⁹Social Determinants of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ³³⁰Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. ³³¹Department of Internal Medicine, John H. Stroger, Jr Hospital of Cook County, Chicago, IL, USA. ³³²Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan. ³³³Department of Epidemiology and Biostatistics, Health Services Academy, Islamabad, Pakistan. ³³⁴Department of Population Studies, International Institute for Population Sciences, Mumbai, India. ³³⁵Department of Population Science, Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh. ³³⁶Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK. ³³⁷College of Arts and Sciences, Ohio University, Zanesville, OH, USA. ³³⁸Department of Medical Parasitology, Cairo University, Cairo, Egypt. ³³⁹Global Evidence Synthesis Initiative, Datta Meghe Institute of Medical Sciences, Wardha, India. ³⁴⁰Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁴¹The Iranian Academy of Medical Sciences, Tehran, Iran. ³⁴²Department of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran. ³⁴³Deputy for Public Health, Ministry of Health and Medical Education, Tehran, Iran. ³⁴⁴Health Equity Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³⁴⁵Department of Public Health, New Mexico State University, Las

Cruces, NM, USA. ³⁴⁶Department of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ³⁴⁷School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia. ³⁴⁸Department of Nutrition, Simmons University, Boston, MA, USA. ³⁴⁹School of Health Sciences, Kristiania University College, Oslo, Norway. ³⁵⁰Global Community Health and Behavioral Sciences, Tulane University, New Orleans, LA, USA. ³⁵¹Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway. ³⁵²Department of Public Health, Ambo University, Ambo, Ethiopia. ³⁵³Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. ³⁵⁴Brain Engineering Research Center, Institute for Research in Fundamental Sciences, Tehran, Iran. ³⁵⁵Independent Consultant, Jakarta, Indonesia. ³⁵⁶Department of Internal and Pulmonary Medicine, Sheri Kashmir Institute of Medical Sciences, Srinagar, India. ³⁵⁷CIBERSAM, San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain. ³⁵⁸Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. ³⁵⁹Department of Zoology, University of Oxford, Oxford, UK. ³⁶⁰Harvard Medical School, Harvard University, Boston, MA, USA. ³⁶¹Department of Anthropology, Panjab University, Chandigarh, India. ³⁶²Department of Demography, University of Montreal, Montreal, Quebec, Canada. ³⁶³Department of Social and Preventive Medicine, University of Montreal, Montreal, Quebec, Canada. ³⁶⁴Department of Psychiatry, University of Nairobi, Nairobi, Kenya. ³⁶⁵Division of Psychology and Language Sciences, University College London, London, UK. ³⁶⁶International Institute for Population Sciences, Mumbai, India. ³⁶⁷Imperial College Business School, Imperial College London, London, UK. ³⁶⁸Faculty of Public Health, University of Indonesia, Depok, Indonesia. ³⁶⁹Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. ³⁷⁰Nuffield Department of Population Health, University of Oxford, Oxford, UK. ³⁷¹National Institute of Health Research (NIHR), Tehran University of Medical Sciences, Tehran, Iran. ³⁷²Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ³⁷³Department of Essential Medicines and Health Products, Clinton Health Access Initiative, Boston, MA, USA. ³⁷⁴Department of Community and Family Medicine, University of Baghdad, Baghdad, Iraq. ³⁷⁵HelpMeSee, New York, NY, USA. ³⁷⁶Mexican Institute of Ophthalmology, Queretaro, Mexico. ³⁷⁷Department of Otorhinolaryngology, Father Muller Medical College, Mangalore, India. ³⁷⁸School of Pharmacy, Monash University, Bandar Sunway, Malaysia. ³⁷⁹School of Pharmacy, Taylor's University Lakeside Campus, Subang Jaya, Malaysia. ³⁸⁰School of Nursing, Hong Kong Polytechnic University, Hong Kong, China. ³⁸¹School of Public Health, Wolaita Sodo University, Wolaita Sodo, Ethiopia. ³⁸²School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. ³⁸³Chinese Center for Disease Control and Prevention, Beijing, China. ³⁸⁴David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ³⁸⁵Center for Integration of Data and Health Knowledge, Oswald Cruz Foundation (FIOCRUZ), Salvador, Brazil. ³⁸⁶Centre for Global Mental Health (CGMH), London School of Hygiene & Tropical Medicine, London, UK. ³⁸⁷Grants, Innovation and Product Development Unit, South African Medical Research Council, Cape Town, South Africa. ³⁸⁸Department of Public Health, Urmia University of Medical Science, Urmia, Iran. ³⁸⁹Department of Clinical Physiology, Tribhuvan University, Kathmandu, Nepal. ³⁹⁰Department of Forensic Medicine, Rajiv Gandhi University of Health Sciences, Dharwad, India. ³⁹¹Department of Forensic Medicine, Shri Dharmasthala Manjunatheshwara University, Dharwad, India. ³⁹²Clinical Research Development Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ³⁹³Department of Humanities and Social Sciences, Indian Institute of Technology, Roorkee, Roorkee, India. ³⁹⁴Department of Development Studies, International Institute for Population Sciences, Mumbai, India. ³⁹⁵Department of Maternal and Child Nursing and Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil. ³⁹⁶Department of Health Education and Promotion, Iran University of Medical Sciences, Tehran, Iran. ³⁹⁷Campus Caucaia, Federal Institute of Education, Science and Technology of Ceará, Caucaia, Brazil. ³⁹⁸Faculty of Health and Education, Botho University-Botswana, Gaborone, Botswana. ³⁹⁹CF International, DHS Program, Rockville, MD, USA. ⁴⁰⁰Neurology Department, Janakpuri Super Speciality Hospital Society, New Delhi, India. ⁴⁰¹Department of Neurology, Govind Ballabh Institute of Medical Education and Research, New Delhi, India. ⁴⁰²Nutrition Health Research Center, Iran University of Medical Sciences, Hamadan, Iran. ⁴⁰³Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. ⁴⁰⁴Institute of Human Virology, University of Maryland, Baltimore, MD, USA. ⁴⁰⁵Peru Country Office, United Nations Population Fund (UNFPA), Lima, Peru. ⁴⁰⁶Forensic Medicine Division, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ⁴⁰⁷Department of Midwifery, Adigrat University, Adigrat, Ethiopia. ⁴⁰⁸Department of Reproductive Health and Population Studies, Bahir Dar University, Bahir Dar, Ethiopia. ⁴⁰⁹Clinical Microbiology and Parasitology Unit, Dr Zora Profozic Polyclinic, Zagreb, Croatia. ⁴¹⁰University Centre Varazdin, University North, Varazdin, Croatia. ⁴¹¹Department of Epidemiology and Biostatistics, Bahir Dar University, Bahir Dar, Ethiopia. ⁴¹²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. ⁴¹³Department of Computer Science and Software Engineering, University of Western Australia, Perth, Western Australia, Australia. ⁴¹⁴Fatemeh Zahra Infertility and Reproductive Health Center, Babol University of Medical Sciences, Babol, Iran. ⁴¹⁵Internal Medicine Programme, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. ⁴¹⁶Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan. ⁴¹⁷Comprehensive Research Laboratory, Iran University of Medical Sciences, Tehran, Iran. ⁴¹⁸Water Quality Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁴¹⁹Department of Rehabilitation and Sports Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁴²⁰Department of Medical Immunology, Tehran University of Medical Sciences, Tehran, Iran. ⁴²¹Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. ⁴²²Institute of Addiction Research (ISF), Frankfurt University of Applied Sciences, Frankfurt, Germany. ⁴²³Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ⁴²⁴Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ⁴²⁵Department of Forestry, Salahaddin University-Erbil, Erbil, Iraq. ⁴²⁶Department of Medicine-Huddinge, Karolinska Institute, Stockholm, Sweden. ⁴²⁷Internal Medicine Department, King Saud University, Riyadh, Saudi Arabia. ⁴²⁸Department of Biology, Salahaddin University-Erbil, Erbil, Iraq. ⁴²⁹Department of Biostatistics, Hamadan University of Medical Sciences, Hamadan, Iran. ⁴³⁰Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran. ⁴³¹Department of Nursing, Mashhad University of Medical Sciences, Mashhad, Iran. ⁴³²Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria. ⁴³³School of Pharmacy, Haramaya University, Harar, Ethiopia. ⁴³⁴Department of Public Health, Dire Dawa University, Dire Dawa, Ethiopia. ⁴³⁵Clinical Epidemiology and Public Health Research Unit, Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy. ⁴³⁶Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. ⁴³⁷Health Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran. ⁴³⁸Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁴³⁹Department of Epidemiology and Biostatistics, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁴⁴⁰National Center for Health Insurance Research, Iran Health Insurance Organization, Tehran, Iran. ⁴⁴¹Computer, Electrical, and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia. ⁴⁴²Department of Clinical Biochemistry, Babol University of Medical Sciences, Babol, Iran. ⁴⁴³Department of Clinical Biochemistry, Tarbiat Modares University, Tehran, Iran. ⁴⁴⁴Department of Food Science, University of Campinas (Unicamp), Campinas, Brazil. ⁴⁴⁵Federal Institute for Population Research, Wiesbaden, Germany. ⁴⁴⁶Center for Population and Health, Wiesbaden, Germany. ⁴⁴⁷Indian Institute of Public Health, Public Health Foundation of India, Hyderabad, India. ⁴⁴⁸Department of Microbiology and Immunology, Mekelle University, Mekelle, Ethiopia. ⁴⁴⁹Research and Analytics Department, Initiative for Financing Health and Human Development, Chennai, India. ⁴⁵⁰Department of Research and Analytics, Bioinsilico Technologies, Chennai, India. ⁴⁵¹Suraj Eye Institute, Nagpur, India. ⁴⁵²Department for the Control of Disease, Epidemics, and Pandemics, Ministry of Public Health, Yaoundé, Cameroon. ⁴⁵³Department of Public Health, University of Yaoundé I, Yaoundé, Cameroon. ⁴⁵⁴Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Manipal, India. ⁴⁵⁵Department of Pediatrics, Arak University of Medical Sciences, Arak, Iran. ⁴⁵⁶Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa. ⁴⁵⁷Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁴⁵⁸Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania. ⁴⁵⁹Department of Biological Sciences, University of Embu, Embu, Kenya. ⁴⁶⁰Institute for Global Health Innovations, Duy Tan University, Da Nang, Vietnam. ⁴⁶¹Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam. ⁴⁶²Institute for Mental Health and Policy, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. ⁴⁶³Department of Clinical Epidemiology, Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada. ⁴⁶⁴Department of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran. ⁴⁶⁵Hormozgan University of Medical Sciences, Bandar Abbas, Iran. ⁴⁶⁶Public Health Department, Universitas Negeri Semarang, Kota Semarang, Indonesia. ⁴⁶⁷Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan. ⁴⁶⁸School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. ⁴⁶⁹Department of Preventive Medicine, Kyung Hee University, Dongdaemun-gu, South Korea. ⁴⁷⁰Gorgan Congenital Malformations Research Center, Golestan University of Medical Sciences, Gorgan, Iran. ⁴⁷¹Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada. ⁴⁷²Department of Psychiatry, University of Lagos, Lagos, Nigeria. ⁴⁷³Centre for Healthy Start Initiative, Lagos, Nigeria. ⁴⁷⁴Diplomacy and Public Relations Department, University of Human Development, Sulaimaniyah, Iraq. ⁴⁷⁵Department of Public Health, Jijiga University, Jijiga, Ethiopia. ⁴⁷⁶Department of Pharmacology and Therapeutics, University of Nigeria Nsukka, Enugu, Nigeria. ⁴⁷⁷Department of Medicine, University of Ibadan, Ibadan, Nigeria. ⁴⁷⁸Department of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ⁴⁷⁹Department of Respiratory Medicine, Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India. ⁴⁸⁰Department of Forensic Medicine, Manipal Academy of Higher Education, Mangalore, India. ⁴⁸¹Department of Parasitology and Mycology, Shiraz University of Medical Sciences, Shiraz, Iran. ⁴⁸²Department of Health Metrics, Center for Health Outcomes & Evaluation, Bucharest, Romania. ⁴⁸³Department of Research, Public Health Foundation of India, Gurugram, India. ⁴⁸⁴Infectious Disease Research Center, National Institute of Public Health, Cuernavaca, Mexico. ⁴⁸⁵Environmental Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁴⁸⁶Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ⁴⁸⁷School of Medicine, University of Sinu, Cartagena, Colombia. ⁴⁸⁸Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia. ⁴⁸⁹Population Health Theme, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia. ⁴⁹⁰Department of Physiology, Iran University of Medical Sciences, Tehran, Iran. ⁴⁹¹Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁴⁹²Center for Research and Innovation, Ateneo De Manila University, Pasig City, The Philippines. ⁴⁹³Department of Cardiology, University of Bern, Bern, Switzerland. ⁴⁹⁴Institute of Microbiology and Immunology, University of Ljubljana, Ljubljana, Slovenia. ⁴⁹⁵University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁴⁹⁶School of Economics and Business, University of Groningen, Groningen, The Netherlands. ⁴⁹⁷Department of Nutrition and Food Sciences, Maragheh University of Medical Sciences, Maragheh, Iran. ⁴⁹⁸Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran. ⁴⁹⁹School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. ⁵⁰⁰Department of Emergency Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵⁰¹Clinical Research Center, Valle del Lili Foundation (Centro de Investigaciones Clínicas, Fundación Valle del Lili), Cali, Colombia. ⁵⁰²PROESA, ICESI University (Centro PROESA, Universidad ICESI), Cali, Colombia. ⁵⁰³Department of Neurology, Smt. B.K.S. Medical Institute and Research Center, Vadodra, India. ⁵⁰⁴Department of Community Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India. ⁵⁰⁵Department of Chemistry, Sharif University of Technology, Tehran, Iran. ⁵⁰⁶Biomedical Engineering Department, Amirkabir University of Technology, Tehran, Iran. ⁵⁰⁷College of Medicine, University of Central Florida, Orlando, FL, USA. ⁵⁰⁸Department of Immunology, Mazandaran University of Medical Sciences, Sari, Iran. ⁵⁰⁹Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran. ⁵¹⁰Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁵¹¹Metabolomics and Genomics Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁵¹²College of Medicine & Health Sciences, University of Gondar, Gondar, Ethiopia. ⁵¹³Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁵¹⁴Research Department, Policy Research Institute, Kathmandu, Nepal. ⁵¹⁵Health and Public Policy Department, Global Center for Research and Development, Kathmandu, Nepal. ⁵¹⁶Department of Oral Pathology, Srinivas Institute of Dental Sciences, Mangalore, India. ⁵¹⁷Institute of Collective Health, Federal

University of Bahia, Salvador, Brazil. ⁵¹⁸Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Mangalore, India. ⁵¹⁹Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. ⁵²⁰Academic Public Health England, Public Health England, London, UK. ⁵²¹WHO Collaborating Centre for Public Health Education and Training, Imperial College London, London, UK. ⁵²²University College London Hospitals, London, UK. ⁵²³School of Health, Medical and Applied Sciences, CQ University, Sydney, New South Wales, Australia. ⁵²⁴Department of Computer Science, Boston University, Boston, MA, USA. ⁵²⁵Department of Mathematical Demography & Statistics, International Institute for Population Sciences, Mumbai, India. ⁵²⁶School of Nursing and Midwifery, Royal College of Surgeons in Ireland - Bahrain, Muharrag Governorate, Bahrain. ⁵²⁷School of Social Sciences and Psychology, Western Sydney University, Penrith, New South Wales, Australia. ⁵²⁸Translational Health Research Institute, Western Sydney University, Penrith, New South Wales, Australia. ⁵²⁹Department of Health Information Management, Manipal Academy of Higher Education, Manipal, India. ⁵³⁰Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa. ⁵³¹Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USAERN), Tehran, Iran. ⁵³²Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran. ⁵³³Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. ⁵³⁴Epidemiology Research Unit Institute of Public Health (EPIUnit-ISPUP), University of Porto, Porto, Portugal. ⁵³⁵Department of Surgery, University of Minnesota, Minneapolis, MN, USA. ⁵³⁶Department of Surgery, University Teaching Hospital of Kigali, Kigali, Rwanda. ⁵³⁷Research Department, Faculty of Medical Sciences, National University of Caaguazú, Coronel Oviedo, Paraguay. ⁵³⁸Department of Research and Publications, National Institute of Health, Asunción, Paraguay. ⁵³⁹Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil. ⁵⁴⁰School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. ⁵⁴¹Department of Biomedical Sciences, University of Sassari, Sassari, Italy. ⁵⁴²Department of Internal Medicine, University of Botswana, Gaborone, Botswana. ⁵⁴³Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. ⁵⁴⁴Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. ⁵⁴⁵Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁵⁴⁶Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India. ⁵⁴⁷Halal Research Center of IRI, Food and Drug Administration of the Islamic Republic of Iran, Tehran, Iran. ⁵⁴⁸Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ⁵⁴⁹Department of Phytochemistry, Soran University, Soran, Iraq. ⁵⁵⁰Department of Nutrition, Cihan University-Erbil, Erbil, Iraq. ⁵⁵¹Department of Anatomical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵⁵²Department of Microbiology, Central University of Punjab, Bathinda, India. ⁵⁵³Urology Department, Cairo University, Cairo, Egypt. ⁵⁵⁴Public Health and Community Medicine Department, Cairo University, Giza, Egypt. ⁵⁵⁵Center for Health Policy & Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA. ⁵⁵⁶Department of Entomology, Ain Shams University, Cairo, Egypt. ⁵⁵⁷Department of Community Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India. ⁵⁵⁸PSG-FAIMER South Asia Regional Institute, Coimbatore, India. ⁵⁵⁹Department of Health and Society, Faculty of Medicine, University of Applied and Environmental Sciences, Bogota, Colombia. ⁵⁶⁰National School of Public Health, Carlos III Health Institute, Madrid, Spain. ⁵⁶¹Department of Community Medicine, Mahatma Gandhi Memorial Medical College, Indore, India. ⁵⁶²Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. ⁵⁶³Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁵⁶⁴Department of Geriatrics and Long Term Care, Hamad Medical Corporation, Doha, Qatar. ⁵⁶⁵Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK. ⁵⁶⁶Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. ⁵⁶⁷Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA. ⁵⁶⁸Emergency Department, Manian Medical Centre, Erode, India. ⁵⁶⁹Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK. ⁵⁷⁰Department of Health Services Management, Iran University of Medical Sciences, Tehran, Iran. ⁵⁷¹Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ⁵⁷²Public Health Division, An-Najah National University, Nablus, Palestine. ⁵⁷³Independent Consultant, Karachi, Pakistan. ⁵⁷⁴Neurology Department, Ain Shams University, Cairo, Egypt. ⁵⁷⁵School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. ⁵⁷⁶Department of Sports Medicine and Rehabilitation, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵⁷⁷Faculty of Caring Science, Work Life and Social Welfare, University of Borås, Borås, Sweden. ⁵⁷⁸HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran. ⁵⁷⁹Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK. ⁵⁸⁰Division of General Internal Medicine, Harvard University, Boston, MA, USA. ⁵⁸¹Health Information Management, Iran University of Medical Sciences, Tehran, Iran. ⁵⁸²Department of Community Medicine, Manipal Academy of Higher Education, Manipal, India. ⁵⁸³National Institute of Infectious Diseases, Tokyo, Japan. ⁵⁸⁴College of Medicine, Yonsei University, Seoul, South Korea. ⁵⁸⁵Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. ⁵⁸⁶Cancer Biology Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁵⁸⁷Department of Health Education and Health Promotion, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁵⁸⁸School of Health, University of Technology Sydney, Sydney, New South Wales, Australia. ⁵⁸⁹Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. ⁵⁹⁰Department of Dermatology, George Washington University, Washington, DC, USA. ⁵⁹¹Department of Law, Economics, Management and Quantitative Methods, University of Sannio, Benevento, Italy. ⁵⁹²WSB University in Gdańsk, Gdańsk, Poland. ⁵⁹³School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ⁵⁹⁴Medicine Service, USA Department of Veterans Affairs (VA), Birmingham, AL, USA. ⁵⁹⁵Department of Epidemiology, School of Preventive Oncology, Patna, India. ⁵⁹⁶Department of Epidemiology, Healis Sekhsaria Institute for Public Health, Mumbai, India. ⁵⁹⁷Program Services Unit, Pathfinder International, Addis Ababa, Ethiopia. ⁵⁹⁸Nursing Care Research Center, Semnan University of Medical Sciences, Semnan, Iran. ⁵⁹⁹Department of Infectious Diseases, Kharkiv National Medical University, Kharkiv, Ukraine. ⁶⁰⁰Hull York Medical School, University of Hull, Hull, UK. ⁶⁰¹Department of Parasitology and Mycology, Tabriz University of Medical Sciences, Tabriz, Iran. ⁶⁰²Division of Community Medicine, International Medical University, Kuala Lumpur, Malaysia. ⁶⁰³Nursing, Muhammadiyah University of Surakarta, Surakarta, Indonesia. ⁶⁰⁴Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria. ⁶⁰⁵Department of Agriculture and Food Systems, University of Melbourne, Melbourne, Victoria, Australia. ⁶⁰⁶Department of Statistics, Manonmaniam Sundaranar University, Abishekapatti, India. ⁶⁰⁷National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India. ⁶⁰⁸Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. ⁶⁰⁹Non-communicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. ⁶¹⁰University Institute 'Egas Moniz', Monte da Caparica, Portugal. ⁶¹¹Research Institute for Medicines, University of Lisbon, Lisbon, Portugal. ⁶¹²Department of Public Health, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁶¹³School of Public Health, University of Adelaide, Adelaide, South Australia, Australia. ⁶¹⁴Department of Environmental Health, Wollo University, Dessie, Ethiopia. ⁶¹⁵Department of Community and Family Medicine, Iran University of Medical Sciences, Tehran, Iran. ⁶¹⁶Department of Public Health, Adigrat University, Adigrat, Ethiopia. ⁶¹⁷Department of Pharmacognosy, Mekelle University, Mekelle, Ethiopia. ⁶¹⁸Department of Medical Microbiology, University of Gondar, Gondar, Ethiopia. ⁶¹⁹Department of Public Health and Community Medicine, Central University of Kerala, Kasaragod, India. ⁶²⁰Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland. ⁶²¹Agency for Health Technology Assessment and Tariff System, Warsaw, Poland. ⁶²²Department of Pathology and Legal Medicine, University of São Paulo, Ribeirão Preto, Brazil. ⁶²³Modestum, London, UK. ⁶²⁴Department of Health Economics, Hanoi Medical University, Hanoi, Vietnam. ⁶²⁵Institute for Physical Activity and Nutrition, Deakin University, Melbourne, Queensland, Australia. ⁶²⁶School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, Australia. ⁶²⁷Department of Allied Health Sciences, Iqra National University, Peshawar, Pakistan. ⁶²⁸Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Nigeria. ⁶²⁹Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India. ⁶³⁰Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India. ⁶³¹Alzakra Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. ⁶³²Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ⁶³³Clinical Cancer Research Center, Milad General Hospital, Tehran, Iran. ⁶³⁴Department of Microbiology, Islamic Azad University, Tehran, Iran. ⁶³⁵Argentine Society of Medicine, Buenos Aires, Argentina. ⁶³⁶Velez Sarsfield Hospital, Buenos Aires, Argentina. ⁶³⁷Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran. ⁶³⁸Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy. ⁶³⁹Department of Economics, University of Göttingen, Göttingen, Germany. ⁶⁴⁰Foundation University Medical College, Foundation University Islamabad, Islamabad, Pakistan. ⁶⁴¹Department of Statistics, University of Washington, Seattle, WA, USA. ⁶⁴²Department of Biostatistics, University of Washington, Seattle, WA, USA. ⁶⁴³Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China. ⁶⁴⁴Demographic Change and Aging Research Area, Federal Institute for Population Research, Wiesbaden, Germany. ⁶⁴⁵Competence Center of Mortality-Follow-Up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany. ⁶⁴⁶Department of Physical Therapy, Naresuan University, Phitsanulok, Thailand. ⁶⁴⁷School of Pharmacy, Aksum University, Aksum, Ethiopia. ⁶⁴⁸Department of Pharmacology and Toxicology, Mekelle University, Mekelle, Ethiopia. ⁶⁴⁹Department of Pharmacology, Addis Ababa University, Addis Ababa, Ethiopia. ⁶⁵⁰Department of Orthopaedics, Wenzhou Medical University, Wenzhou, China. ⁶⁵¹Psychology Department, University of Sheffield, Sheffield, UK. ⁶⁵²Department of Diabetes and Metabolic Diseases, University of Tokyo, Tokyo, Japan. ⁶⁵³School of International Development and Global Studies, University of Ottawa, Ottawa, Ontario, Canada. ⁶⁵⁴The George Institute for Global Health, University of Oxford, Oxford, UK. ⁶⁵⁵Health Services Management Research Center, Kerman University of Medical Sciences, Kerman, Iran. ⁶⁵⁶Department of Health Management, Policy, and Economics, Kerman University of Medical Sciences, Kerman, Iran. ⁶⁵⁷School of Nursing, Hawassa University, Hawassa, Ethiopia. ⁶⁵⁸Pediatrics Department, University of Jos, Jos, Nigeria. ⁶⁵⁹Department of Pediatrics, Jos University Teaching Hospital, Jos, Nigeria. ⁶⁶⁰Centre for Suicide Research and Prevention, University of Hong Kong, Hong Kong, China. ⁶⁶¹Department of Social Work and Social Administration, University of Hong Kong, Hong Kong, China. ⁶⁶²Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan. ⁶⁶³Department of Public Health, Juntendo University, Tokyo, Japan. ⁶⁶⁴Department of Health Policy and Management, Jackson State University, Jackson, MS, USA. ⁶⁶⁵School of Medicine, Tsinghua University, Beijing, China. ⁶⁶⁶Department of Environmental Health, Mazandaran University of Medical Sciences, Sari, Iran. ⁶⁶⁷Injury Prevention and Safety Promotion Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁶⁶⁸Duke Global Health Institute, Duke University, Durham, NC, USA. ⁶⁶⁹Social Determinants of Health Research Center, Ardabil University of Medical Science, Ardabil, Iran. ⁶⁷⁰The School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia. ⁶⁷¹Student Research Committee, Babol University of Medical Sciences, Babol, Iran. ⁶⁷²Department of Community Medicine, Ardabil University of Medical Science, Ardabil, Iran. ⁶⁷³Department of Health Education, Tarbiat Moarefa University, Tehran, Iran. ⁶⁷⁴College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia. ⁶⁷⁵Public Health Department, University of Edinburgh, Edinburgh, UK. ⁶⁷⁶School of Public Health, Wuhan University of Science and Technology, Wuhan, China. ⁶⁷⁷Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China. ⁶⁷⁸School of Medicine, Wuhan University, Wuhan, China. ⁶⁷⁹School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, China. ⁶⁸⁰School of Health Sciences, Wuhan University, Wuhan, China. ⁶⁸¹National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. ⁶⁸²These authors jointly supervised this work: Simon I. Hay, Stephen S. Lim, Jonathan F. Mosser. ⁶⁸³e-mail: shihay@uw.edu; stevelim@uw.edu; jmosser@uw.edu

Methods

Data reporting

As this is a modelling study, no statistical methods were used to pre-determine sample size, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.

Overview

Building from our previous study of diphtheria–tetanus–pertussis vaccination coverage in Africa¹⁴, we fitted a geostatistical model with correlated errors across space and time to predict 5×5 -km² level estimates of MCV1 coverage from 2000 to 2019 using a suite of geospatial and national-level covariates for 101 LMICs. This overall process has been summarized in Extended Data Fig. 1. We spatially aggregated estimates using population-weighted averages to second administrative units from a modified version of the Database of Global Administrative Units (GADM), referred to as districts, and performed post hoc analyses to assess geographical inequality to examine progress towards GVAP targets, absolute geographical inequality and vaccination status as a function of geographical remoteness⁵. This study is compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) recommendations⁵¹ (Supplementary Table 1).

We defined routine MCV1 coverage as evidence of receipt of at least one dose of a MCV from either a home-based record (HBR) or parental recall among the target population in concordance with country-specific vaccination schedules in 2019⁵². Despite our best efforts to remove doses delivered through supplemental immunization activities (SIAs) (Supplementary Information section 1.3.4), there is likely to be residual misclassification of some SIA doses due to the limitations of the available data, and these estimates of routine coverage should be viewed in the context of this limitation.

Countries were selected for this analysis if they were a LMIC or were a 'Decade of Vaccine' priority country with available subnational survey data on MCV1 coverage between 2000 and 2019⁵³. We defined LMICs based on the socio-demographic index, a metric combining education, fertility and income to summarize development, as determined by GBD 2019⁵⁴. For 13 countries (Bhutan, Brazil, China, Dominica, Georgia, Grenada, Libya, Oman, Palestine, Saint Lucia, Saint Vincent and the Grenadines, Seychelles and Venezuela), no available subnational vaccine coverage data met the inclusion and exclusion criteria; these countries were therefore excluded from this analysis. A full list of included countries is provided in Supplementary Table 3. Countries were assigned to one of 13 continuous geographical modelling regions. These regions were adapted from regions defined by GBD 2019, which are constructed to group countries together by epidemiological similarity and geographical proximity (Extended Data Fig. 2).

Data

Using the Global Health Data Exchange (GHDx)⁵⁵, we identified and compiled a total of 354 population-based household surveys from 101 LMICs from 2000 to 2019 containing individual MCV1 vaccination status and subnational geolocation information. Surveys were included if they contained MCV1 coverage information and subnational geolocation, and excluded if they contained areal data and were missing key survey design variables (strata, primary sampling units and design weights), did not include children aged 12–59 months, contained no subnational individual-level geographical information or if coverage estimates were implausible (Supplementary Tables 4, 5).

Coverage was computed at the cluster level when global positioning system (GPS) data were available. If GPS information was not collected or was not available, we calculated mean coverage at the most-granular geographical area possible while accounting for sampling weights and survey design. These aggregated coverage estimates were then included in the geospatial modelling process using a

previously described method^{14,56} that leverages population weights and a *k*-means clustering algorithm to propose a set of GPS coordinates as a proxy for locations where survey data collection could have occurred (Supplementary Fig. 3). These coordinates were then used to represent the areal data in the geospatial model. The following data were extracted from each survey source: vaccine card or HBR doses, parental recall vaccine doses, age (in months), survey weight and design variables, and GPS cluster or areal location. Individuals with evidence of vaccination either from HBR or recall were considered to have been vaccinated. Individuals were excluded from the analysis if they were missing age, spatial or survey design information or were outside of the study age or year range. The study included all years between 2000 and 2019. A comprehensive overview of data from all study geographies included can be found in Supplementary Figs. 1, 2.

Individual age, in months, at the time of survey collection was used to assign each child to a birth cohort (12–23 months, 24–35 months, 36–47 months and 48–59 months). Data corresponding to each birth cohort were included in the modelling process in the year in which that birth cohort was aged 0–12 months old. For countries recommending MCV1 within the first year of life, we included data from children aged 12–47 months. If the first dose was not recommended until the second year of life, we included data from children aged 24–59 months. A full list of schedules by country can be found in Supplementary Table 2. This yielded a dataset of 1,697,570 total children. This method allows the inclusion of additional individuals, which increases overall geographical representation but requires assumptions such as negligible catch-up vaccination and no differential mortality or migration. However, the overall influence of including older cohorts in our model on the key findings appeared to be minor (Supplementary Information section 2.2). Additional information on the benefits and limitations of this approach can be found in the Supplementary Information sections 1.3.4, 2.2, Supplementary Figs. 18–20 and Supplementary Tables 14, 15.

We included 26 geospatial covariates as possible predictors of MCV1 coverage in the modelling process, including maternal education, access to major cities or settlements, a binary urban or rural indicator, total population and a suite of 22 environmental covariates (Supplementary Fig. 4 and Supplementary Table 6). Four national-level covariates were also included: lag-distributed income, prevalence of the completion of the fourth antenatal care visit among pregnant women, mortality due to war and terror, and bias-adjusted national-level administrative data on MCV1 coverage reported through the WHO/UNICEF Joint Reporting Form (Supplementary Information section 1.5.1). For each region, an optimized set of geospatial covariates was selected from these 26 possible covariates, using a variance inflation factor (VIF) algorithm⁵⁷ in which covariates were selected with a VIF < 3. This method was used to ensure non-collinearity between covariates within each region to facilitate model convergence. Selected covariates varied by region (Supplementary Table 7).

Other spatial data used in our analyses included gridded population estimates, administrative boundaries and gridded estimates of travel time to major cities or settlements. These sources are described in detail in Supplementary Information section 1.3.

Geostatistical model

First, stacked generalization was used to capture potential nonlinear and complex relationships between covariates and vaccination coverage. This approach has previously been shown to increase the predictive accuracy of geospatial models⁵⁸. Using the optimized set of covariates selected for each region by the VIF algorithm, three different child models—generalized additive models, lasso regression and boosted regression trees—were fit, with each model predicting MCV1 coverage as the outcome of interest. When fitting boosted regression trees, country-level fixed effects were included to allow relationships between coverage and covariates to differ by country. In this initial modelling step, there were no explicitly defined temporal or spatial

Article

effects included in the models beyond those inherently present in the covariate patterns and correlations between covariates.

Each child model was fit using fivefold cross-validation to avoid overfitting. This generated out-of-sample predictions of coverage for each location and year per region. Each model in each region was also fit using the full set of vaccine coverage outcome data, which yielded a corresponding set of in-sample predictions. The predictions of MCV1 coverage obtained from each child model were in turn used as predictors in the second-step geostatistical model described below. Out-of-sample predictions from each child model were used as explanatory covariates when fitting the geostatistical model. In-sample predictions from each model and region were used when generating predictions from the fitted geostatistical model.

After the first step (stacked generalization), a second-step Bayesian geostatistical modelling framework was used to model vaccination coverage as counts in a binomial space with a logit link through a generalized linear regression with explicit spatial and temporal terms. This second step leverages the covariate relationships estimated through stacked generalization while also accounting for additional correlation in coverage across space and time.

A separate model of MCV1 coverage was fit for each of the 13 regions as defined below:

$$C_d | p_{i(d),t(d)}, N_d \sim \text{Binomial}(p_{i(d),t(d)}, N_d) \forall \text{ observed clusters } d$$

$$\text{logit}(p_{i,t}) = \beta_0 + X_{i,t} \beta + Z_{i,t} + \epsilon_{\text{country}(i)} + \epsilon_{i,t} \quad i \in \text{spatial domain} \quad \forall t \in \text{time domain}$$

$$\sum_{h=1}^3 \beta_h = 1$$

$$\epsilon_{i,t} \sim \mathcal{N}(0, \sigma_{\text{nugget}}^2)$$

$$\epsilon_{\text{country}(i)} \sim \mathcal{N}(0, \sigma_{\text{country}(i)}^2)$$

$$Z \sim \text{GP}(0, \Sigma^{\text{space}} \otimes \Sigma^{\text{time}})$$

$$\Sigma^{\text{space}} = \frac{2^{1-\nu} \sigma_{\text{space}}^2}{\Gamma(\nu)} \times \left(\frac{\sqrt{8}}{\delta} D \right)^\nu \times K_\nu \left(\frac{\sqrt{8}}{\delta} D \right)$$

$$\Sigma_{j,k}^{\text{time}} = \rho^{|k-j|}$$

This model, adopted from widely used Bayesian hierarchical models^{59,60}, has been described in detail in other work^{14,25,56,61,62}. In brief, this method estimates the number of children, C , in cluster d at location i and time t with sample size N that have been vaccinated with a specific antigen-dose combination. $p_{i(d),t(d)}$ is the proportion of children vaccinated with MCV1 among the target age population in cluster d . Each child model generates a prediction $X_{i,t}$ for each child model h . Residual terms ϵ are unique to each particular location in space and time across all modelled geographies and years.

In this generalized linear regression framework, the proportion of children vaccinated $p_{i,t}$ is modelled using the out-of-sample predictions of vaccine coverage $X_{i,t}$ from each of three stacked generalization child models (h) as explanatory variables. The β_h coefficients are constrained to sum to 1, via the ‘extraconstr’ R-INLA parameter⁶³, to improve computational tractability⁵⁸ and are representative of the predictive weighting used in the stacking process.

$\epsilon_{\text{country}(i)}$ represents a country-level random effect. $\epsilon_{i,t}$ represents an independent nugget effect for irreducible error for a given observation, which accounts for true variation that is unable to be captured by the

model and variation from measurement error. $Z_{i,t}$ represents a correlated spatiotemporal error term, for any residual autocorrelation across space and time that remains after accounting for the predictive capacity of the stacked-modelled covariates, country-specific variation in vaccine coverage and observation-specific irreducible error.

These additional spatiotemporal residuals $Z_{i,t}$ were modelled as a three-dimensional spatiotemporal Gaussian process with a mean of zero and a covariance matrix formed from the Kronecker product of spatial and temporal covariance kernels. The temporal covariance Σ^{time} was modelled via an annual autoregressive order 1 function from all study years from 2000 to 2019, where ρ is the autocorrelation function and k and j are points in the annual time series. The spatial covariance Σ^{space} was assumed to be an isotropic, stationary Matérn function, where Γ is the gamma function, K_ν is the modified Bessel function of the second kind of order $\nu > 0$, σ_{space}^2 is the marginal variance, ν is a scaling constant, δ is a range parameter with a penalized complexity prior, and D is a spatial distance matrix⁶⁴, measured along the great circle in kilometres. The generalized linear model was fitted using an integrated nested Laplace approximation in R-INLA with a stochastic partial differential equation (SPDE) solver in package SPDE⁶⁵. Additional detailed information on priors, spatial mesh construction and model fitting is provided in Supplementary Information sections 1.4.2–1.4.6 and Supplementary Fig. 5. This process produces a set of 1,000 posterior draws, each representing an estimate of vaccine coverage for each location and year—in other words, a set of 1000 candidate maps of coverage from 2000 to 2019.

Post-estimation

To leverage data from additional national-level sources, including administrative data, and maintain internal consistency, the set of candidate maps was calibrated to MCV1 coverage estimates produced for GBD 2019. This post hoc calibration preserves the overall spatial variation of estimates, while ensuring that the population-weighted averages of the geospatial estimates are equivalent to those produced by GBD⁴. This step allows for the calibrated estimates to reflect information from data sources that are only available at the national level, such as surveys for which no subnational data are available, which are included in the GBD estimates but excluded from the geospatial model described in the ‘Geostatistical model’ section. A description of the estimation of MCV1 coverage for GBD 2019 can be found in Supplementary Information section 1.5.1.

In this calibration process, each $5 \times 5\text{-km}^2$ pixel in each modelled region was first assigned to a second-level administrative unit. In locations in which boundary definitions transect a given pixel, the fraction of area of that pixel belonging to each overlapping second-level administrative unit was calculated. Because of the nested hierarchy of administrative units, this additionally allowed for the assignment of pixels and partial pixels to first administrative units and countries. Assuming that the population density within each pixel was uniform, WorldPop population values of children under 5 years old were divided for each whole or partial pixel proportional to fractional area. After pixel and partial pixel populations were assigned, population-level estimates were calibrated to GBD population estimates for each country and year.

Calibration methods similar to those used in this study have been described previously¹⁴. To ensure vaccination coverage estimates post-calibration remained between 0 and 100%, calibration was performed in logit space such that for each country c and year t , national-level estimates of coverage from GBD ($V_{\text{GBD},c,t}$) and population-weighted national averages of coverage from the model-based geostatistical (MBG) model ($V_{\text{MBG},c,t}$) can be related via a country-year-specific calibration factor ($k_{c,t}$) in the following equation:

$$\text{logit}(V_{\text{GBD},c,t}) = \text{logit}(V_{\text{MBG},c,t}) + k_{c,t}$$

Calibration factors were applied to each 5 × 5-km² pixel and partial pixel per draw per country-year. Pixels that were fractionally assigned to multiple countries were combined using a weighted average proportional to the fraction of each area. This process resulted in a set of calibrated draw-level estimates of vaccination coverage, which were used for all subsequent analyses.

Population-weighted averages of coverage for each pixel or partial pixel within a first or second administrative unit were then calculated. Fractional pixel membership was determined as described above. This process was repeated for each of the 1,000 posterior pixel-level draws, which yielded 1,000 posterior draws of MCV1 coverage per administrative unit per year. Estimates for first and second administrative units with uncertainty were derived from mean, 2.5th and 97.5th percentiles.

Model validation

We assessed the predictive performance of the models using fivefold out-of-sample cross-validation. We stratified data by first and second administrative units and ran models leaving out one-fifth of the spatially stratified data at a time. Predicted estimates of MCV1 coverage were then compared to the withheld observed data by calculating the mean error, root mean square error, correlation and other predictive validity metrics for all years for which survey data were available (2000–2018). Fitted model parameters can be found in Supplementary Table 8. Metrics and validity figures can be found in Supplementary Tables 9–12 and Supplementary Figs. 6–13, respectively. Additional information regarding uncertainty of estimates can be found in Supplementary Figs. 14–17.

Post hoc geospatial inequality analyses

Lorenz curves were generated using the relationship between the number of children and the number of vaccinated children for each pixel. Pixel-level Gini coefficients were calculated for 2000 and 2019 from corresponding Lorenz curves^{66,67} (Supplementary Table 13). Absolute geographical inequality per country was calculated from the national-level Gini coefficients and national MCV1 coverage using the following formula:

$$\text{Absolute geographical inequality} = 2 \times \text{coverage} \times \text{Gini}$$

We chose to use the absolute geographical inequality metric to represent inequality over the Gini coefficient alone. As the mean is related to Gini, we wanted to account for this relationship. Estimates are scaled by 2 as this puts the absolute geographical inequality coefficient back to the same scale as the mean⁶⁸.

Additionally, we assessed vaccination status as a function of geographical remoteness. Using a gridded surface of travel time to major cities or settlements, we classified each 5 × 5-km² pixel as remote rural, urban or neither²⁹. Pixels with travel times of less than 30 min were classified as urban, and pixels with travel times greater than 3 h were classified as remote rural. Overlaid with a gridded population surface from WorldPop³⁰, the number of unvaccinated children per pixel was also calculated.

We constructed concentration curves of the cumulative proportion of unvaccinated children as well as plots of MCV1 coverage by travel time to assess patterns across countries and regions. Country-specific concentration curves of the cumulative proportion of unvaccinated children as a function of travel time for select countries are shown in Extended Data Fig. 10. Summary metrics, such as the proportion of unvaccinated individuals living in each urban and remote rural location, were computed.

Limitations

This work is subject to several limitations. First, the primary data used in this analysis came from child-level survey data with varying degrees of representativeness, consistency, accuracy and comparability, from

both HBR and parental recall^{69,70}. The magnitude and direction of recall bias varies, and we therefore were unable to correct for it⁷¹. We estimate coverage using data from children aged 12–59 months, and while we accounted for target age at vaccination, this does not fully account for differential mortality due to vaccine status or catch-up vaccination. We aim to estimate routine coverage and have excluded doses delivered via SIAs from the analysed survey data wherever possible (Supplementary Information section 1.3.4), but misclassification of SIA doses is still likely, particularly in cases of parental recall—especially for older children—and in cases in which survey methodology does not distinguish clearly between SIA and routine doses.

In data-sparse areas for which covariate relationships may not fully capture coverage patterns, results may be biased. Additionally, data representativeness among vulnerable populations, such as those living in urban slums or migrant populations, might vary due to data collection in survey design. We include as much data on MCV1 coverage as possible, including data that are only geo-resolved to areal locations. The methodology that we used to assign areal data to specific locations for modelling could lead to oversmoothing in final estimates, obscure relationships between coverage and covariates, and underestimate uncertainty, but this method has been shown to have a higher predictive validity compared with the exclusion of the data⁷². Limitations due to data availability should not be taken lightly and should reinforce to stakeholders and policymakers the need for additional resources to collect high-quality data that are representative of all populations, especially the most vulnerable for being unvaccinated, and to increase the quality of routinely collected subnational administrative data.

Because the estimates that we used to assess geographical remoteness in post hoc analyses were also used as spatial covariates in the geospatial model, these results are limited by the possibility of circularity and subsequent confounding. In addition, we used a stacked generalization method to allow for complex and nonlinear relationships between covariates and vaccination coverage. These methods are optimized for prediction, not causal inference. For that reason, these results cannot be used to identify the specific effect of any particular covariate on MCV1 coverage. In addition, owing to limitations in the underlying data and computational feasibility, we were unable to incorporate several potentially important sources of uncertainty into this analysis, including from covariates, population estimates, the incorporation of areal data and the stacked generalization process.

We fitted our geostatistical models using R-INLA, as opposed to a full Markov chain Monte Carlo sampler. Although using a more traditional Bayesian model fitting approach that takes true samples from the posterior typically results in increased parameter identifiability, the Laplace approximation approach used by R-INLA is more computationally feasible given our current modelling scale. Our model is separable, yet symmetric, across time and space. This approach assumes that, for each region, the covariance has the same functional form between years and locations regardless of the locations themselves; the use of a non-separable covariance function could relax these assumptions^{73,74}. However, owing to the additional computational challenges associated with fitting a non-separable model, as well as data sparsity in several regions throughout space and time, we determined that fitting a non-separable model would be challenging and complex, and would probably yield little benefit compared to our current modelling approach.

In some settings with high levels of natural immunity (derived from previous infection), greater than 95% vaccination coverage may not be required to prevent disease transmission⁷⁵. These estimates only focus on the first routine dose of MCV, and immunity can also be obtained through later vaccination via SIA or natural infection. In an ideal long-term measles elimination scenario, all immunity would be vaccine-derived, and no natural infections would occur. A 95% coverage target for routine immunization, therefore, still has practical programmatic relevance.

Article

Finally, our study describes spatial heterogeneity in coverage, but not pockets of low coverage within social or age groupings that can facilitate ongoing disease transmission, particularly in densely populated areas, despite nominally high average vaccine coverage⁷⁶. Although these results provide a powerful tool for policymakers to identify weaknesses in routine immunization systems and plan for SIA, they should be used in conjunction with other data sources that can be used to make decisions about vaccine policy, including analyses of cost effectiveness, determinants of high or low coverage, and specific coverage initiatives to reduce disease burden.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

The findings of this study are supported by data available in public online repositories and data publicly available upon request from the data provider. A detailed table of data sources and availability can be found in Supplementary Table 4 and at <http://ghdx.healthdata.org/lbd-publication-data-input-sources>. Administrative boundaries were modified from the Database for Global Administrative Areas (GADM) dataset⁷⁷. Populations were retrieved from WorldPop³⁰, and gridded estimates of travel time to the nearest city or settlement were available online from a previously published study²⁹. This study complies with the GATHER recommendations⁵¹.

Code availability

This study is compliant with the GATHER recommendations⁵¹; as such, all computer code is available from GitHub (<https://github.com/ihmeuw/lbd/tree/mcv1-lmic-2020>). All maps and figures presented in this study are generated by the authors using RStudio (R version 3.6.1), ArcGIS Desktop 10.6 and Python 2.7.

- Stevens, G. A. et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. *Lancet* **388**, e19–e23 (2016).
- World Health Organization. *WHO Vaccine-preventable Diseases: Monitoring System. 2020 Global Summary. Immunization Schedule by Disease covered by Antigens within Age Range Selection Centre*. https://apps.who.int/immunization_monitoring/globalsummary/diseases (2019).
- WHO. *Decade of Vaccines — Global Vaccine Action Plan 2011–2020*. https://www.who.int/immunization/global_vaccine_action_plan/DoV_GVAP_2012_2020/en/ (accessed 30 April 2020).
- GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1995–2051 (2018).
- Institute for Health Metrics and Evaluation. *Global Health Data Exchange (GHDx)*. <http://ghdx.healthdata.org/> (2019).
- Osgood-Zimmerman, A. et al. Mapping child growth failure in Africa between 2000 and 2015. *Nature* **555**, 41–47 (2018).
- Faraway, J. J. *Linear Models with R* (Chapman and Hall/CRC, 2009).
- Bhatt, S. et al. Improved prediction accuracy for disease risk mapping using Gaussian process stacked generalization. *J. R. Soc. Interface* **14**, 20170520 (2017).
- Banerjee, S., Carlin, B. P. & Gelfand, A. E. *Hierarchical Modeling and Analysis for Spatial Data* (Chapman and Hall/CRC, 2014).
- Cressie, N. & Wikle, C. K. *Statistics for Spatio-Temporal Data* (Wiley, 2011).
- Reiner, R. C. Jr et al. Variation in childhood diarrheal morbidity and mortality in Africa, 2000–2015. *N. Engl. J. Med.* **379**, 1128–1138 (2018).
- Golding, N. et al. Mapping under-5 and neonatal mortality in Africa, 2000–15: a baseline analysis for the Sustainable Development Goals. *Lancet* **390**, 2171–2182 (2017).
- Gomez-Rubio, V. *Bayesian Inference with INLA* (Chapman and Hall/CRC, 2020).
- Stein, M. L. *Interpolation of Spatial Data: Some Theory for Kriging* (Springer-Verlag, 1999).
- Martins, T. G., Simpson, D., Lindgren, F. & Rue, H. Bayesian computing with INLA: new features. *Comput. Stat. Data Anal.* **67**, 68–83 (2013).
- De Maio, F. G. Income inequality measures. *J. Epidemiol. Community Health* **61**, 849–852 (2007).
- Sen, A. et al. *On Economic Inequality* (Clarendon, 1997).
- Ray, D. *Development Economics* (Princeton Univ. Press, 1998).
- Cutts, F. T., Claquin, P., Danovaro-Holliday, M. C. & Rhoda, D. A. Monitoring vaccination coverage: defining the role of surveys. *Vaccine* **34**, 4103–4109 (2016).
- Cutts, F. T., Izurieta, H. S. & Rhoda, D. A. Measuring coverage in MNCH: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys. *PLoS Med.* **10**, e1001404 (2013).

- Dansereau, E., Brown, D., Stashko, L. & Danovaro-Holliday, M. C. A systematic review of the agreement of recall, home-based records, facility records, BCG scar, and serology for ascertaining vaccination status in low and middle-income countries. *Gates Open Res.* **3**, 923 (2020).
- Marquez, N. & Wakefield, J. Harmonizing child mortality data at disparate geographic levels. Preprint at <https://arxiv.org/abs/2002.00089> (2020).
- Stein, M. L. Space–time covariance functions. *J. Am. Stat. Assoc.* **100**, 310–321 (2005).
- Gneiting, T. Nonseparable, stationary covariance functions for space–time data. *J. Am. Stat. Assoc.* **97**, 590–600 (2002).
- Perisic, A. & Bauch, C. T. Social contact networks and disease eradicability under voluntary vaccination. *PLoS Comput. Biol.* **5**, e1000280 (2009).
- Streefland, P., Chowdhury, A. M. R. & Ramos-Jimenez, P. Patterns of vaccination acceptance. *Soc. Sci. Med.* **49**, 1705–1716 (1999).
- Global Administrative Areas. *GADM Maps and Data*. v.3.6 <https://gadm.org/> (2019).

Acknowledgements This work was primarily supported by grants from the Bill & Melinda Gates Foundation (OPP1182474, OPP11093011 and OPP1132415). S.I.H. is funded by additional grants from the Bill & Melinda Gates Foundation (OPP119467 and OPP1106023). The opinions expressed in this paper are those of the authors and not necessarily those of the World Health Organization. J.-W.D.N. was supported by the Alexander von Humboldt Foundation. C.H. is partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084, and a grant co-funded by the European Fund for Regional Development through Operational Program for Competitiveness, Project ID P_40_382_Y.J.K. acknowledges support by the Research Management Centre, Xiamen University Malaysia (XMUMRF/2018-C2/ITCM/0001). K. Krishan is supported by a DST PURSE Grant and UGC Centre of Advanced Study awarded to the Department of Anthropology, Panjab University, Chandigarh, India. B.L. acknowledges support from the NIHR Oxford Biomedical Research Centre and the BHF Centre of Research Excellence, Oxford. M.A.M. acknowledges NIGEB and NIMAD grants. A. Sheikh acknowledges support by Health Data Research UK. S.B.Z. acknowledges support from the Australian Government research training program (RTP) for his academic career.

Author contributions J.F.M., A.N.S., S.S.L. and S.I.H. conceived and planned the study. A.N.S., J.F.M., S.R., J.Q.N. and N.C.G. identified and vetted data for this analysis. S.R. and J.Q.N. extracted, processed and geo-positioned the data. A.N.S. carried out the statistical analyses with assistance and input from J.F.M., S.S.L. and C.J.L.M. A.N.S., L.E., S.R. and J.Q.N. prepared figures and tables. A.N.S. wrote the first draft of the manuscript with assistance from J.F.M., S.S.L., S.I.H. and M.K.M.-P. and all authors contributed to subsequent revisions. All authors provided intellectual input into aspects of this study.

Competing interests This study was funded by the Bill & Melinda Gates Foundation. Authors employed by the Bill & Melinda Gates Foundation provided feedback on initial maps and drafts of this manuscript. Otherwise, the funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the final report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. O.O.A. is supported by DSI-NRF Centre of Excellence for Epidemiological Modelling and Analysis (SACEMA). C.A.T.A. reports personal fees from Johnson & Johnson (The Philippines), outside the submitted work. M.L.B. reports grants from the US Environmental Protection Agency, the National Institutes of Health (NIH) and the Wellcome Trust Foundation, during the conduct of the study. M.L.B. also reports honoraria and/or travel reimbursements from the NIH (for the review of grant proposals), *American Journal of Public Health* (participation as editor), Global Research Laboratory and Seoul National University, Royal Society London UK, Ohio University, Atmospheric Chemistry Gordon Research Conference, Johns Hopkins Bloomberg School of Public Health, Arizona State University, Ministry of the Environment Japan, Hong Kong Polytechnic University, University of Illinois–Champaign, and University of Tennessee–Knoxville. S. Basu reports grants from the NIH, grants from the US Centers for Disease Control and Prevention, grants from the US Department of Agriculture, grants from Robert Wood Johnson Foundation, personal fees from Research Triangle Institute, personal fees from Collective Health, personal fees from KPMG, personal fees from HealthRight360, personal fees from *PLoS Medicine*, personal fees from *The New England Journal of Medicine*, outside the submitted work. F.D. reports grants from the Bill & Melinda Gates Foundation, during the conduct of the study. A. Deshpande reports grants from the Bill & Melinda Gates Foundation, during the conduct of the study. S.J.D. reports grants from The Fleming Fund at the UK Department of Health & Social Care, during the conduct of the study. S.M.S.I. received funding from the National Heart Foundation of Australia. J.J.J. reports personal fees from AMGEN, personal fees from ALAB, personal fees from TEVA, personal fees from SYNEXUS, personal fees from BOEHRINGER INGELHEIM and personal fees from VALEANT, outside the submitted work. H.J.L. reports grants from GSK, outside the submitted work. W.M. is Program Analyst in Population and Development at the United Nations Population Fund (UNFPA), an institution which does not necessarily endorse this study. T. Pilgrim reports grants and personal fees from Biotronik, grants and personal fees from Boston Scientific and grants from Edwards Lifesciences, outside the submitted work. M.J.P. reports grants and personal fees from MSD, GSK, Pfizer, Boehringer Ingelheim, BMS, Novavax, Astra Zeneca, Sanofi, IQVIA and other pharmaceutical industries, personal fees from Quintiles, Novartis, Pharmierit and Seqirus, grants from Bayer, BioMerieux, WHO, EU, FIND, Antilope, DIKTI, LPDP, Budi, and other from Ingress Health, Pharmacoeconomics Advice Groningen (PAG Ltd), Asc Academics, outside the submitted work. M.J.P. holds stocks in Ingress Health and PAG Ltd and is advisor to Asc Academics, all of which are pharmacoeconomic consultancy companies, outside of submitted work. J. A. Singh reports personal fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio Health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, Practice Point Communications, the NIH and the American College of Rheumatology, personal fees from the speaker's bureau of Simply Speaking, stock options in Amarin Pharmaceuticals and Viking Pharmaceuticals, non-financial support from the steering committee of OMERACT, an international organization that develops measures

for clinical trials and receives arm's length funding from 12 pharmaceutical companies, outside of the submitted work. J. A. Singh serves on the FDA Arthritis Advisory Committee, is a member of the Veterans Affairs Rheumatology Field Advisory Committee, and is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis, all outside the submitted work. R.U. reports other financial activities from Deakin University, outside the submitted work. J.F.M. reports grants from the Bill and Melinda Gates Foundation, during the conduct of the study.


Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41586-020-03043-4>.

Correspondence and requests for materials should be addressed to S.I.H., S.S.L. or J.F.M.

Peer review information *Nature* thanks C. Edson Utazi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.


Reprints and permissions information is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | Data processing and geospatial modelling flowchart.


Survey data and the suite of covariates used in modelling are first compiled and processed (orange and grey). The modelling process (purple) consists of data being used in a stacked generalization ensemble modelling process via boosted regression tree, lasso and generalized additive models, fitting the second-stage spatiotemporal model using integrated nested Laplace

approximation, and finally calibration to GBD estimates (blue). Steps in dark green and outputs in yellow indicate the post-estimation process when the full posterior distribution of predictions is transformed to both $5 \times 5\text{-km}^2$ and first and second administrative-unit-level maps and their various final results. Intermediate outputs throughout the process are shown in blue and overall processes are shown in light green.




Extended Data Fig. 2 | Regions of countries used in modelling. Analyses were divided into 13 regions based on the GBD super-regions to allow for locations similar in data availability and patterns of vaccine coverage to be

analysed using similar covariate and modelling relationships. Each colour represents a different region, as described in the legend.




Extended Data Fig. 3 | National, first- and second-administrative-unit level, and pixel-level MCV1 coverage, 2000. a–d, Posterior means are represented at the national (a), first-administrative-unit (b), second-administrative-unit (c)

and $5 \times 5\text{-km}^2$ pixel (d) levels. Pixels that are grey in colour are either not included in the analysis, or have been classified as being 'barren or sparsely vegetated' or had fewer than 10 people per $1 \times 1\text{-km}^2$ pixel^{30,50}.




Extended Data Fig. 4 | National, first- and second-administrative level, and pixel-level MCV1 coverage, 2005. a–d. Posterior means are represented at the national (a), first-administrative-unit (b), second-administrative-unit (c) and

5 × 5-km² pixel (d) levels. Pixels that are grey in colour are either not included in the analysis, or have been classified as being 'barren or sparsely vegetated' or had fewer than 10 people per 1 × 1-km² pixel^{30,50}.




Extended Data Fig. 5 | National, first- and second-administrative-unit level, and pixel-level MCV1 coverage, 2010. a–d, Posterior means are represented at the national (a), first-administrative-unit (b), second-administrative-unit (c)

and $5 \times 5\text{-km}^2$ pixel (d) levels. Pixels that are grey in colour are either not included in the analysis, or have been classified as being 'barren or sparsely vegetated' or had fewer than 10 people per $1 \times 1\text{-km}^2$ pixel^{30,50}.




Extended Data Fig. 6 | National, first- and second-administrative-unit level, and pixel-level MCV1 coverage, 2015. a – d. Posterior means are represented at the national (a), first-administrative-unit (b), second-administrative-unit (c)

and $5 \times 5\text{-km}^2$ pixel (d) levels. Pixels that are grey in colour are either not included in the analysis, or have been classified as being 'barren or sparsely vegetated' or had fewer than 10 people per $1 \times 1\text{-km}^2$ pixel^{30,50}.




Extended Data Fig. 7 | National, first- and second-administrative-unit level, and pixel-level MCV1 coverage, 2019. a – d. Posterior means are represented at the national (a), first-administrative-unit (b), second-administrative-unit (c)

and $5 \times 5\text{-km}^2$ pixel (d) levels. Pixels that are grey in colour are either not included in the analysis, or have been classified as being 'barren or sparsely vegetated' or had fewer than 10 people per $1 \times 1\text{-km}^2$ pixel^{30,50}.







Extended Data Fig. 8 | Probability of increased or decreased coverage from 2000 to 2010 and 2010 to 2019. a–d, Probability of an increase in coverage in each district (a, b) and probability of decrease in coverage in each district (c, d) from 2000 to 2010 (a, c) and 2010 to 2019 (b, d).



Extended Data Fig. 9 | Estimated district-level probabilities of reaching MCV1 coverage targets in 2019. a, b. Probability of districts having achieved 80% GVAP and Measles Rubella Initiative targets (a) and 95% critical proportion to immunize coverage targets to reach herd immunity (b). Countries excluded

from the analysis and pixels classified as 'barren or sparsely vegetated' based on ESA-CCI satellite data or with fewer than 10 people per $1 \times 1\text{-km}^2$ pixel based on WorldPop estimates are masked in grey^{30,50}.



Extended Data Fig. 10 | Country examples of concentration curves. Concentration curves of the cumulative proportion of unvaccinated children as a function of travel time (in hours) in Chad (a), Madagascar (b), India (c) and Mexico (d). Curves for both the indicated countries (blue) and all LMICs (grey) are shown.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No primary data collection was carried out for this analysis.
Data analysis	This analysis was carried out using R version 3.6.1 and using R-INLA v.20.01.29.9000. Maps were produced using ArcGIS Desktop 10.6 and Python 2.7. All code used for these analyses will be made publicly available upon publication.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The findings of this study are supported by data available in public online repositories and data publicly available upon request of the data provider. A detailed table of data sources and availability can be found in Supplementary Table 4 and <http://ghdx.healthdata.org/lbd-publication-data-input-sources>. Administrative boundaries were modified from the Database for Global Administrative Areas (GADM) dataset. Populations were retrieved from WorldPop and gridded estimates of travel time to nearest city or settlement were available online from work by Weiss, et al 2018. This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) recommendations. All maps and figures presented in this study are generated by the authors; no permissions are required for publication.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	This observational study incorporated all available survey data sources that met the inclusion criteria as described in detail in the manuscript and supplementary information. The combined dataset from 354 household based surveys contained information on vaccination status from 1.70 million individual children.
Data exclusions	Surveys were excluded due to unrealistic national or geographic trends compared to other surveys in nearby country-years, inability to match the microdata to geographic locations, or non-standard methodology. These criteria were pre-established prior to reviewing the data. A full list of excluded surveys is included in Supplementary Table 5.
Replication	All code and data are available publicly for reproducibility.
Randomization	As this work is an observational mapping study, there were no experimental groups.
Blinding	As this work is an observational mapping study, there was no need for blinding.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging